The Role of Cardiac Myocyte Dimensions in the Transition from Hypertensive Hypertrophy to Cardiac Dilatation

Raúl José Correia

Dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Science in Medicine

Johannesburg, 2010
DECLARATION

I, Raúl José Correia declare that this dissertation is my own, unaided work. It is being submitted for the degree of Master of Science in Medicine, in the Faculty of Medicine, University of the Witwatersrand, Johannesburg. The work contained in this thesis has not been submitted before for any degree or examination in this university, or any other university.

………………………………………………………………………………………………………..

RAÚL JOSÉ CORREIA

……………………………………day of ……………………………., 2010

I certify that the studies contained in this thesis have the approval of the Animal Ethics Committee of the University of the Witwatersrand, Johannesburg. The ethics approval numbers are: 97:44:5, 99:01:2b, 2002:37:5, 2002:39:5 and 2006:41:05.

………………………………………………………………………………………………………..

RAÚL JOSÉ CORREIA

……………………………………day of ……………………………., 2010

…………………………………..                                           ………………………..

ANGELA J. WOODIWISS (Supervisor) GAVIN R. NORTON (Supervisor)
Dedication:
For my parents,
Augusto and Jeanette
de Paiva Correia
PUBLICATIONS AND PRESENTATIONS

Data presented in this dissertation have been published in a manuscript of which I am third author, namely,


In addition, data presented in this dissertation have been presented in the form of an oral presentation, as well as in a poster at the 33rd Meeting of the Physiology Society of Southern Africa Conference in Cape Town, September 2005. The titles of these presentations were,

Correia RJ, Norton GR & Woodiwiss AJ. Cardiomyocyte lengthening does not contribute to the development of cardiac dilatation (oral presentation)

Woodiwiss A, Correia R, Norton G, Muller C & Strijdom H. Determination of cardiomyocyte length using flow cytometry (poster presentation)
ABSTRACT

The progression from compensated cardiac hypertrophy to decompensation and cardiac failure is accompanied by cardiac dilatation. As cardiac failure has a poor prognosis, it is imperative to prevent the progression to cardiac dilatation and heart failure. In this regard, an understanding of the mechanisms of cardiac dilatation is vital to guide optimal therapy to prevent heart failure. Although a number of factors have been shown to contribute to the development of cardiac dilatation, to date the role of alterations in cardiac myocyte dimensions remains unclear. Hence, the aim of the current study was to determine whether changes in cardiac myocyte dimensions contribute to the process of cardiac dilatation.

Methods: Two models of cardiac dilatation in pressure-overload induced cardiac hypertrophy were assessed. One model was a natural progression model, in which 18 spontaneously hypertensive rats (SHR), were assessed at 23 months of age (an age when left ventricular hypertrophy is noted to have progressed to left ventricular decompensation, dilatation and heart failure in approximately 50% of rats). The second model, a pharmacological model, was induced in 14 month old SHR (n=9) by chronic beta-adrenoreceptor activation [0.02mg/kg isoproterenol (ISO) twice daily for 4.5 months]. Chronic beta-adrenoreceptor activation in SHR, enhances the progression from compensated left ventricular hypertrophy to left ventricular dilatation. Nine normotensive Wistar Kyoto (WKY) rats were the controls for both models. Left ventricular dilatation was defined as an increase in left ventricular radius determined at controlled filling pressures using piezo-electric transducers. The classification of rats as being in heart failure was based upon the presence of pleuropericardial effusions and / or atrial thrombi. Cardiac myocytes were isolated and dimensions determined using both light microscopy and flow cytometry.

Results: Left ventricular radius was increased in SHR-Failure compared to SHR-Non-Failure (p<0.01), and in SHR-ISO compared to SHR-Control (saline administration) (p<0.01), hence confirming the presence of cardiac dilatation in both models. Although, cardiac myocyte length
was increased in all SHR groups compared to WKY (p<0.001), no differences were observed between SHR-Failure and SHR-Non-Failure, or between SHR-ISO and SHR-Control. No differences in cell length:width ratios or in cell widths were evident between the groups. The flow cytometry data confirmed the results obtained for cardiac myocyte lengths using microscopy. Moreover, a linear correlation (r=0.46, p=0.002) between flow cytometry and microscopy cardiac myocyte lengths was observed. Importantly, no relationships were evident between left ventricular radius and cardiac myocyte length (r=0.12, p=0.42 and r=0.14, p=0.35 for microscopic and flow cytometry lengths respectively).

Conclusion: The results from the present study show that although pressure-overload hypertrophy is associated with lengthening of cardiac myocytes, no further changes occur with cardiac dilatation. Hence, alterations in cardiac myocyte dimensions do not contribute to the development of cardiac dilatation in pressure-overload models.
ACKNOWLEDGEMENTS

I am grateful for the assistance of the Central Animal Services of the University of the Witwatersrand. I would like to thank Mr Ernest Somya and Dr Oleg Osadchii for their invaluable assistance. I would also like to thank Prof. A Woodiwiss and Prof. G Norton for their guidance.

Funding for these studies was obtained from grants awarded to Prof. A Woodiwiss from the South African National Research Foundation, and to Prof. G Norton from the Medical Research Council of South Africa. The Cardiovascular Pathophysiology and Genomics Research Unit, the School of Physiology and Faculty of Health Sciences of the University of the Witwatersrand also supported these studies.
# TABLE OF CONTENTS

| Declaration | ii |
| Dedication | iii |
| Publications and Presentations | iv |
| Abstract | v |
| Acknowledgements | vii |
| Table of Contents | viii |
| List of Figures | x |
| List of Tables | xi |
| Abbreviations | xii |
| Preface | xiv |

## CHAPTER 1

### 1.0 INTRODUCTION

### 1.1 CARDIAC DILATATION AND HEART FAILURE

1.1.1 Definition of Cardiac Dilatation

1.1.2 Appropriate Measurements of Cardiac Dilatation

1.1.3 Role of Cardiac Dilatation in the Development of Heart Failure

1.1.4 How Does Cardiac Dilatation Produce Pump Dysfunction?

### 1.2 MEDIATORS OF CARDIAC HYPERTROPHY AND ADVERSE CARDIAC REMODELLING

1.2.1 Role of Neurohormones in Compensatory Cardiac Hypertrophy and the Progression to Cardiac Decompensation and Heart Failure

1.2.1.1 Role of the Sympathetic Nervous System

1.2.1.2 Role of the Renin-Angiotensin-Aldosterone System

1.2.2 Role of Growth Factors and Inflammatory Cytokines

1.2.3 Role of Stretch Receptors (Cardiac Myocyte Stretch)

### 1.3 PROPOSED MECHANISMS OF COMPENSATORY CARDIAC HYPERTROPHY

1.3.1 Role of Collagen and Interstitial Changes

1.3.2 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell Width

### 1.4 PROPOSED MECHANISMS OF ADVERSE CARDIAC REMODELLING

1.4.1 Role of Collagen and Interstitial Changes

1.4.2 Role of Cardiac Myocyte Apoptosis and Necrosis

1.4.3 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell Length

1.4.3.1 Are Changes in Cardiac Dimensions Associated with Changes in Cardiac Myocyte Length?

1.4.3.1.1 Data from Human Studies

1.4.3.1.2 Data from Animal Experimental Models

### 1.5 PROBLEM STATEMENT AND STUDY OBJECTIVES

---

## CHAPTER 2

### 2.0 METHODS

### 2.1 RAT STRAINS AND GROUPS

2.1.1 Natural Progression Model

2.1.2 Pharmacological Model

### 2.2 SYSTOLIC BLOOD PRESSURE

### 2.3 LEFT VENTRICULAR GEOMETRY

2.3.1 Identification of Failure and Non-Failure Rats

### 2.4 TISSUE SAMPLING

### 2.5 MYOCYTE ISOLATION

### 2.6 LIGHT MICROSCOPY

### 2.7 FLOW CYTOMETRY
## 2.8 Statistical Analyses

### CHAPTER 3

#### 3.0 RESULTS

#### 3.1 LEFT VENTRICULAR GEOMETRY

- **3.1.1 Natural Progression Model**
  - 3.1.1.1 Body and Tissue Weights and Blood Pressures
  - 3.1.1.2 LV Dimensions

- **3.1.2 Pharmacological Model**
  - 3.1.2.1 Body and Tissue Weights
  - 3.1.2.2 LV Dimensions

#### 3.2 MYOCYTE DIMENSIONS

- **3.2.1 Natural Progression Model**
  - 3.2.1.1 Light Microscopy
  - 3.2.1.2 Flow Cytometry

- **3.2.2 Pharmacological Model**
  - 3.2.2.1 Light Microscopy
  - 3.2.2.2 Flow Cytometry

#### 3.3 CORRELATIONS

- **3.3.1 Left Ventricular End Diastolic Radius and Cardiac Myocyte Length**
- **3.3.2 Cardiac Myocyte Lengths Obtained Using Light Microscopy versus Flow Cytometry**
- **3.3.3 Left Ventricular Weight (mg/100g Body Weight) versus Cardiac Myocyte Length**

### CHAPTER 4

#### 4.0 DISCUSSION

### CHAPTER 5

#### 5.0 REFERENCES

### APPENDICES (Animal Ethics Screening Committee Clearance Certificates)
# LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter 1</strong></td>
<td></td>
</tr>
<tr>
<td>1.1 Example of a right-shift in the diastolic pressure-volume relationship</td>
<td>7</td>
</tr>
<tr>
<td>1.2 Example of changes in the Frank-Starling relationship</td>
<td>12</td>
</tr>
<tr>
<td>1.3 Schematic representation showing possible mechanisms of cardiac dilatation</td>
<td>16</td>
</tr>
<tr>
<td>1.4 Schematic representation of the factors known to contribute to cardiac dilatation</td>
<td>37</td>
</tr>
</tbody>
</table>

| **Chapter 2** | |
| 2.1 Flow chart detailing the groups of rats | 42 |
| 2.2 Intraventricular pressure monitoring and piezo-electric ultrasonic transducers | 46 |
| 2.3 Example of recordings of left ventricular external diameter measurements | 47 |
| 2.4 Examples of isolated cardiac myocytes | 53 |
| 2.5 Photograph of digital camera and microscope | 54 |
| 2.6 An example of striations of an isolated cardiac myocyte | 55 |
| 2.7 Flow cytometer | 58 |
| 2.8 Example of flow cytometer dot plot | 59 |
| 2.9 Diagrammatic representation of a cardiac myocyte in the path of the flow cytometer laser beam | 60 |
| 2.10 Plot of cardiac myocyte counts versus time of flight | 61 |

| **Chapter 3** | |
| 3.1 Left ventricular end diastolic radius – pressure relations in the natural progression model | 65 |
| 3.2 Left ventricular end diastolic wall thickness to radius ratio – pressure relations in the natural progression model | 67 |
| 3.3 Left ventricular end diastolic radius – pressure relations in the pharmacological model | 69 |
| 3.4 Left ventricular end diastolic wall thickness to radius ratio – pressure relations in the pharmacological model | 70 |
| 3.5 Cardiac myocyte lengths and frequency distribution of cardiac myocyte lengths in the natural progression model | 72 |
| 3.6 Cardiac myocyte widths and length to width ratios in the natural progression model | 73 |
| 3.7 Cardiac myocyte lengths as assessed by flow cytometry in the natural progression model | 74 |
| 3.8 Cardiac myocyte lengths and frequency distribution of cardiac myocyte lengths in the pharmacological model | 76 |
| 3.9 Cardiac myocyte widths and length to width ratios in the pharmacological model | 77 |
| 3.10 Cardiac myocyte lengths as assessed by flow cytometry in the pharmacological model | 79 |
| 3.11 Linear correlation analyses between left ventricular end diastolic radius and cardiac myocyte length | 80 |
| 3.12 Linear correlation analysis between cardiac myocyte length measured using light microscopy and flow cytometry | 81 |
| 3.13 Linear correlation analyses between left ventricular weight normalised to 100g body weight and cardiac myocyte length as assessed by light microscopy and flow cytometry | 83 |
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter 1</strong></td>
<td></td>
</tr>
<tr>
<td>1.1 Summary of human data addressing possible association of cardiac remodelling with alterations in myocyte morphology</td>
<td>26</td>
</tr>
<tr>
<td>1.2 Summary of data from animal experimental models addressing possible association of cardiac remodelling with alterations in myocyte morphology</td>
<td>30</td>
</tr>
<tr>
<td><strong>Chapter 3</strong></td>
<td></td>
</tr>
<tr>
<td>3.1 Body and tissue weights in the natural progression model and in the pharmacological</td>
<td>64</td>
</tr>
<tr>
<td>model</td>
<td></td>
</tr>
</tbody>
</table>
ABBREVIATIONS

ACE – Angiotensin-converting enzyme
AESC – Animal ethics screening committee
ANOVA – Analysis of variance
ATP – Adenosine triphosphate
CaCl₂ – Calcium chloride
cAMP – Cyclic adenosine monophosphate
CAS – Central animal service
CHF – Congestive heart failure
CO₂ – Carbon dioxide
EDP – End-diastolic ventricular pressure
EDV – End-diastolic ventricular volume
ESV - End-systolic ventricular volume
HEPES- (4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid hemisodium salt
HOCM – Hypertrophic obstructive cardiomyopathy
h/r – relative wall thickness; i.e. LVED wall thickness to LVED radius ratio
IDCM - Idiopathic dilated cardiomyopathy
ISO - Isoproterenol
KCl – Potassium chloride
KH₂PO₄ – Potassium dihydrogen phosphate
LV – Left ventricle
LVAD – Left ventricular assist device
LVDP – Left ventricular diastolic pressure
LVED – Left ventricular end-diastolic
LVEDh – Left ventricular end-diastolic wall thickness
LVEDP – Left ventricular end-diastolic pressure
LVEDr – Left ventricular end-diastolic radius
LVEF – Left ventricular ejection fraction
LVextD – Left ventricular external diameter
MI – Myocardial infarction
MgCl₂ – Magnesium chloride
NaCl – Sodium chloride
NaOH – Sodium hydroxide
O₂ - Oxygen
PNS – Parasympathetic nervous system
PSS - Physiological saline solution
RAAS – Renin-angiotensin-aldosterone system
SBP – Systolic blood pressure
SEM – Standard error of the mean
SHHF – Spontaneously hypertensive heart failure
SHR – Spontaneously hypertensive rat
SNS – Sympathetic nervous system
TNF-α - Tumour Necrosis Factor-α
WKY - Wistar-Kyoto
PREFACE

Cardiovascular disease is one of the leading causes of morbidity and mortality in all parts of the world today. Almost all forms of cardiovascular disease progress to heart failure, which is the terminal endpoint of cardiovascular diseases. Hence, the progression to heart failure needs to be prevented. Chronic cardiovascular disease is initially accompanied by cardiac hypertrophy which is considered compensatory in that cardiac wall stress is maintained within normal levels; however compensatory cardiac hypertrophy progresses to cardiac decompensation and heart failure, a state in which cardiac wall stress is elevated. The increase in cardiac wall stress is primarily due to enlargement of the cardiac chamber volume and thinning of the cardiac chamber wall, a process termed detrimental cardiac remodelling or dilatation. As cardiac failure has a poor prognosis, it is imperative to prevent the progression to cardiac dilatation and heart failure. In this regard, an understanding of the mechanisms of cardiac dilatation is vital to guide optimal therapy to prevent heart failure.

The mechanisms by which the cardiac tissue remodels to cause the dilatation are the topic of much debate. Both changes in the cardiac interstitium as well as changes in the cardiac myocytes are believed to play a role. In previous studies, adverse cardiac remodelling has been associated with increased cardiac interstitial fibrosis, but of the non-cross-linked form; cardiac myocyte apoptosis and necrosis; as well as cardiac myocyte hypertrophy due to changes in cell length. Although, some consensus has been reached regarding the role of the cardiac interstitium and cardiac myocyte death (apoptosis or necrosis); to date the role of alterations in the dimensions of cardiac myocytes remains unclear.

Although, cardiac dilatation is thought to be mediated by increases in the length of cardiac myocytes, not all studies support this hypothesis. Indeed, although some studies show that increases in cardiac myocyte length are associated with increases in cardiac chamber dimensions or heart failure; a number of other studies show no relationship. Furthermore, data from
intervention studies failed to show changes in cardiac dimensions in parallel with changes in cardiac myocyte length. A number of reasons may explain the controversial results regarding the role of alterations in cardiac myocyte length in cardiac dilatation.

Firstly, in some studies the increased cardiac myocyte length in patients with heart failure compared to healthy controls could be as a consequence of the differences in body weight and hence left ventricular (LV) weight between these two groups. The differences in body weight were due to a greater proportion of males in the heart failure group compared to the control group.

Secondly, as the phase of the cardiac cycle determines cardiac chamber dimensions and cardiac myocyte length, possible differences between the heart failure and control groups in the phase of the cardiac cycle at the time of cardiac arrest may account for the differences in cardiac chamber diameter and cardiac myocyte length observed between these two groups in some human studies.

Thirdly, in a number of studies in spontaneously hypertensive heart failure (SHHF) rats showing an association between cardiac myocyte length and cardiac chamber dimension, the animals in heart failure were significantly older than the control animals. As LV weight increases with age in hypertensive rats, and cardiac myocyte length is strongly associated with age and LV weight, the increases in cardiac myocyte length observed in the rats in heart failure may reflect age induced changes, rather than an association with adverse chamber remodelling (cardiac dilatation) and the development of heart failure.

Fourthly, other than the studies in SHHF rats, no other studies have made direct comparisons of animals with cardiac pathology which have heart failure to animals with the same cardiac pathology but without heart failure. However, as discussed the increased cardiac myocyte length in SHHF rats may reflect increased age and hence increased LV weight compared to controls, rather than increased cardiac dimensions. Indeed, it has been shown that cardiac myocyte lengthening increased with age and occurred well before the development of heart failure in SHHF rats. Although the latter study suggests that changes in cardiac myocyte length are not responsible for
the development of heart failure, no measurements of cardiac dimensions were made in this study. To my knowledge no study to date has compared age-matched animals with the same cardiac pathology which have heart failure to those without heart failure.

Lastly, the use of load dependent measures of cardiac chamber dimensions (echocardiography in vivo) in the presence of increased preloads may also contribute to the controversy. In this regard cardiac myocyte lengthening occurs as a consequence of the stretching of cardiac myocytes during increased preloads (filling volume or pressure). Moreover, when pulmonary capillary wedge pressure was normalised as a consequence of LV assist device support, a normalisation of both LV end diastolic diameter and cardiac myocyte length has been reported. Moreover, data from various intervention studies failed to show changes in cardiac dimensions in parallel with changes in cardiac myocyte length and hence the results of these studies do not support a role of changes in cardiac myocyte length in cardiac dilatation. Indeed, if increases in cardiac myocyte length were causally related to adverse cardiac remodelling, a reduction in cardiac myocyte length should be accompanied by a decrease in cardiac chamber dimensions. However, these intervention data need to be interpreted with caution in view of the use of load dependent measures of cardiac dimensions in these studies.

The data to date provides no clear conclusion as to the possible role of cardiac myocyte length in adverse chamber remodelling. Hence, the aim of the current study was to determine whether changes in cardiac myocyte length contribute to the progression from compensatory cardiac hypertrophy to adverse chamber remodelling (cardiac dilatation) as measured using load independent methods in rats with heart failure compared to those not in heart failure.
1.0 INTRODUCTION

One of the leading causes of morbidity and mortality in all parts of the world today is cardiovascular disease (American Heart Association, 2010). Over 80 million adults (more than one in three), in America alone have some form of cardiovascular disease (American Heart Association, 2010). Moreover, cardiovascular disease accounts for 16.7 million of deaths (29.2%) worldwide per annum (Frey et al., 2004). In South Africa, cardiovascular disease was reported to account for ~90 to 100 deaths per 100 000 population in 2006 (Mayosi et al., 2009). In addition, of the total cases reported on in a cardiology unit, at a hospital that services an urban developing community in South Africa, 43% were de novo presentations of heart failure (Stewart et al., 2008). Importantly, almost all forms of cardiovascular disease progress to heart failure, which is the terminal endpoint of cardiovascular diseases. Hence, the progression to heart failure needs to be prevented.

In order to adequately prevent morbidity and mortality from heart failure, an understanding of the mechanisms underlying the progression to heart failure are paramount. In this regard a number of different models of heart failure have been investigated. A major predictor of progressive heart disease and an adverse prognosis is cardiac hypertrophy (Levy et al., 1990). Although, cardiac hypertrophy is initially a compensatory response to alterations in loading conditions (Grossman et al., 1975), prolonged hypertrophy ultimately leads to cardiac dilatation (increase in cardiac chamber dimensions), heart failure and subsequent death (Bing et al., 1995; Inoko et al., 1994; Lorell 1997; Spann et al., 1967). Factors which have been associated with the development of cardiac dilatation and heart failure (decompensation) in various models of cardiac hypertrophy, include unfavourable changes in the cardiac interstitium; enhanced cardiac myocyte apoptosis and necrosis; realignment of cardiac
myocytes within the ventricular walls (myocardial slippage) expression of foetal genes; and alterations in cardiac myocyte dimensions (Cohn et al., 2000; Ferrari et al., 2009; Frigerio & Roubina, 2005; Remme 2003). These changes occur in response to sustained pathological stress signals such as neurohumoral activation, the release of growth factors and inflammatory cytokines, and mechanical stretch (Cohn et al., 2000; Ferrari et al., 2009; Frigerio & Roubina, 2005; Remme 2003). These pathological signals are termed the mediators of adverse cardiac remodelling.

Despite a plethora of studies investigating the various factors associated with the development of heart failure, the role of alterations in cardiac myocyte dimensions in the progression from compensatory cardiac hypertrophy to cardiac dilatation is unclear. In this regard, compensatory cardiac hypertrophy is generally associated with increases in cardiac myocyte width (Onodera et al., 1998; Zierhut et al., 1991); whereas alterations in cardiac myocyte length are thought to contribute to cardiac dilatation (Gerdes 2002). However, most studies showing increases in cardiac myocyte length in association with increases in left ventricular (LV) dimensions have used load dependent measures of cardiac chamber dimensions (Chen et al., 2010; Gerdes et al., 2010; Kajstura et al., 1995; Tamura et al., 1998; Wang et al., 1999; Yarbrough et al., 2010). Thus whether cardiac dilatation has indeed occurred in these studies is debatable. Moreover, although in some studies increases in load dependent measures of cardiac chamber diameter are associated with increases in cardiac myocyte dimensions (Gerdes et al., 2010; Janczewski et al., 2003; Kajstura et al., 1995; Schultz et al., 2007; Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999); other studies fail to show such relationships (Li et al., 2010; Schultz et al., 2007; Tamura et al., 2000; Yarbrough et al., 2010). Nevertheless, an understanding of the role of cardiac myocyte hypertrophy in cardiac dilatation is essential to guide choices of optimal therapy to prevent
the progression from compensatory hypertrophy to decompensation.

Hence, the aim of my studies was to determine the role of alterations in cardiac myocyte dimensions in the progression from concentric cardiac hypertrophy to cardiac dilatation. As the most prevalent form of heart failure is that associated with hypertensive heart disease (Remme et al., 2003), I chose to assess two models of cardiac dilatation in spontaneously hypertensive rats (SHR) with cardiac hypertrophy. Therefore, in the present chapter of my dissertation, I will discuss the role of cardiac dilatation in the development of heart failure and the importance of defining cardiac dilatation using load independent measurements. I will then review the literature on the factors (mediators and mechanisms) associated with the development of cardiac hypertrophy and the progression to decompensation and heart failure, with specific reference to the controversial role of alterations in cardiac myocyte dimensions.

1.1 CARDIAC DILATATION AND HEART FAILURE

In response to chronic elevations in cardiac wall stress (increases in loading conditions, such as chronic hypertension or post myocardial infarction), the heart undergoes hypertrophy (thickening of the ventricular wall) in an attempt to normalise wall stress. According to the law of La Place, wall tension or stress, is proportional to the product of pressure (P) and radius (r) and inversely proportional to wall thickness (h). Hence, an increased wall thickness in cardiac hypertrophy maintains a normal wall stress in the presence of increments in either pressure or volume (radius) within the cavity (Grossman et al., 1975). This process, termed compensatory cardiac hypertrophy, is generally associated with adequate cardiac systolic function, and a normal or increased ventricular wall thickness to radius ratio (Janicki et al., 2004). However, diastolic function may be decreased due to the restriction of ventricular
filling by a thickened ventricular wall (Kai et al., 2005; Norton et al., 1993). The development of compensatory hypertrophy is due to the load-induced activation of various mediators which initiate cellular, molecular and genetic processes.

As will be discussed in more detail later, persistent activation of these mediators over time, and consequently alterations in cellular, molecular and genetic processes eventually leads to cardiac decompensation (Remme, 2003). Cardiac decompensation is associated with a reduced ventricular wall thickness to radius ratio, ventricular enlargement and depressed cardiac systolic function (Janicki et al., 2004). This process of adverse cardiac remodelling (reduced ventricular wall thickness to radius ratio and ventricular enlargement), also termed cardiac dilatation, progresses with time to heart failure. Hence, cardiac dilatation is an important negative prognostic factor in patients with heart failure (Cohn et al., 2000; Udelson et al., 2002). Moreover, even in asymptomatic subjects without a prior history of heart failure, LV dilatation is associated with an increased risk of the development of heart failure (Vasan et al., 1997). It is therefore important to understand how cardiac remodelling contributes to the development of heart failure.

One of the limitations of many studies assessing the role of cardiac remodelling in heart failure, and the mechanisms thereof, is the inability to define cardiac dimensions in a load-independent model. In this regard, increases in cardiac filling volumes (increased preloads) would manifest as increased cardiac dimensions. Moreover, increases in cardiac afterload (increased cardiac wall stress as discussed above) would reduce stroke volume thereby increasing ventricular volumes at the end of systole, which would also manifest as increased cardiac dimensions. Hence, the correct definition of cardiac remodelling is an increase in cardiac diameter, or a decrease in the wall thickness to radius ratio, at a given filling volume.
Therefore, before discussing the impact of cardiac dilatation on cardiac function and the development of heart failure, I will first discuss in more detail the definition of cardiac dilatation and appropriate measurements thereof.

1.1.1 Definition of Cardiac Dilatation

Cardiac chamber dilatation is defined as an increase in chamber cavity volume or dimension as a consequence of a right shift in the diastolic pressure-volume relationship (Figure 1.1). Importantly, cardiac dilatation is not an increase in only the chamber cavity volume, as this may result from an enhanced blood volume or venous return (increased preload) without necessarily being accompanied by a right shift in the diastolic pressure-volume relationship. In addition, cardiac dilatation is not a right shift in the diastolic pressure-volume relationship produced by alterations in the slope of this relationship. Changes in the slope of the cardiac diastolic pressure-volume relationship occur as a consequence of alterations in chamber stiffness, which are usually mediated by modifications in the material properties of the myocardium (Gilbert and Glantz, 1989). However, cardiac chamber dilatation is the consequence of a right shift in the diastolic pressure-volume relationship due to an increase in the volume intercept of this relationship (Gibbs et al., 2004) (Figure 1.1).

1.1.2 Appropriate Measurements of Cardiac Dilatation

As increases in blood volume, venous return, and blood pressure (may decrease stroke volume); and decreases in cardiac contractility can result in increases in ventricular volumes, it is important that filling volumes are controlled when determining the relationship between diastolic pressure and volume. Hence, the in vivo assessment of the diastolic pressure-volume relationship using echocardiographic measures of cardiac dimensions is not appropriate. Indeed, blood volumes are related to body size, which may differ between for example
Figure 1.1  Example of a right-shift in the diastolic pressure-volume relationship

The normal diastolic pressure-volume relationship is indicated by the solid line, and a right shift in the pressure-volume relationship, indicative of cardiac dilatation, is indicated by the dashed line. The volume intercept [volume at which left ventricular (LV) end diastolic pressure equals zero ($V_0$)] is increased in the right shifted relationship.
normotensive and hypertensive rats (Badenhorst et al., 2003a; Tsetotsi et al., 2001; Veliotes et al., 2005). In addition, increases in cardiac afterload, such as increases in blood pressure or peripheral resistance in hypertension, would reduce stroke volume and hence increase filling volumes (more blood is left behind at the end of systole). Moreover, the measurement of cardiac dimensions alone, without the measurement of the accompanying diastolic pressures is not appropriate. Indeed, as diastolic pressure increases, so does diastolic volume (Figure 1.1). Hence, increases in chamber dimensions may be a manifestation of increases in filling pressures (increased preload) rather than measures of true cardiac dilatation.

Nevertheless, many clinical and experimental studies have defined the presence of dilatation using non-invasive measurements such as echocardiography and ventriculography. Hence, whether cardiac dilatation was indeed present is questionable. Indeed increases in filling pressures were noted in many of these studies (Chen et al., 2010; Gerdes et al., 2010; Kajstura et al., 1995; Tamura et al., 1998; Wang et al., 1999; Yarbrough et al., 2010; Zefeiridis et al. 1998). Although in clinical studies there is no alternative to non-invasive measurements; of greater concern is the use of such measurements in terminal experimental studies. In this regard, in many animal based studies, the groups differ in age (Gerdes et al., 1996; Tamura et al., 1998). As age is associated with increased LV weight (Gerdes et al. 1996), and increased left ventricular weight is correlated with cardiac myocyte length (Campbell et al. 1991; Capasso et al. 1992), and age (Tamura et al., 1998), any differences in cardiac dimensions could be attributed to differences in age and hence heart weight rather than true differences in the dimensions of the heart. In other words the increased left ventricular weight and hence cardiac myocyte length is likely to reflect growth effects during aging.
Therefore, in order to appropriately define the presence of cardiac dilatation, ventricular pressures need to be determined and ventricular filling volumes need to be controlled. In this manner the diastolic pressure-volume relationship can be constructed and hence the volume at which pressure is 0 mm Hg (ie. the volume intercept) can be determined. Importantly, very few studies have accurately defined dilatation using pressure-volume relationships. In this regard, no study assessing the role of cardiac myocyte dimensions in heart failure, has accurately defined the presence of dilatation.

1.1.3 Role of Cardiac Dilatation in the Development of Heart Failure

Initially it was thought that cardiac dilatation was a remodeling process that began in order to prevent the progressive increases in filling pressures associated with heart failure (Ertl et al., 1991). In essence, it was believed that the decreased contractility in heart failure and hence increased filling volumes (Patterson and Adams, 1996), were necessary in order to maintain stroke volume via the Frank-Starling effect (Grossman et al., 1975). However, the increased filling volumes would be accompanied by increases in filling pressures and hence pulmonary capillary hydrostatic pressures may be elevated resulting in pulmonary congestion. It was therefore believed that in order to accommodate enhanced filling volumes at normal filling pressures a right shift in the diastolic pressure-volume occurred.

However, more recently, cardiac dilatation has been shown to be a precursor of pump dysfunction and clinical heart failure (Gaudron et al., 1993; Pfeffer et al., 1992; Vasan et al., 1997). In a 3 year prospective study in patients post myocardial infarction, those patients who had progressive dilatation also had a progressive decline in ejection fraction and an increase in pulmonary capillary wedge pressure (Gaudron et al., 1993); whereas in those patients with no dilatation, LV ejection fraction did not decline and pulmonary wedge pressure remained
within normal values. Hence cardiac dilatation post myocardial infarction results in the development of heart failure. In addition, in an 11-year follow-up study of people who had not sustained a myocardial infarction and who did not have congestive heart failure at enrolment, increments in LV internal dimension increased the risk of development of congestive heart failure (adjusted hazard ratio of 1.47 for a one standard deviation increase in LV end diastolic diameter indexed for height) (Vasan et al., 1997). Moreover, intervention studies have shown that the alleviation of LV enlargement post myocardial infarction prolongs survival and reduces mortality and morbidity due to major cardiovascular events (Pfeffer et al., 1992; St John Sutton et al., 1997). Hence, the process of cardiac dilatation has to be seen as a cause of heart failure as opposed to its consequence.

There are a number of additional observations which support the role of cardiac dilatation in the development of heart failure. Firstly, in the presence of compensatory cardiac hypertrophy (increases in wall thickness) in response to pressure overload, there is no evidence of systolic heart failure (Wang et al., 1999; Onodera et al., 1998; Woodiwiss et al., 1995; Yousef et al., 2000). Secondly, the neurohumoral factors that maintain systolic function in the hypertrophied heart, in the long-term are detrimental to the myocardium. Indeed, these neurohumoral factors promote cardiac dilatation and ultimately lead to systolic dysfunction (Woodiwiss et al., 1995; Yousef et al., 2000). Lastly, there is evidence to show that maladaptive changes in myocardial tissue occur long before symptoms of heart failure (Onodera et al., 1998). Hence adverse cardiac remodelling, which consists of both macroscopic and microscopic changes in the myocardium, precedes heart failure and therefore contributes to, instead of results from, heart failure (Onodera et al., 1998). The question of how cardiac dilatation produces pump dysfunction and heart failure therefore arises.
1.1.4 How Does Cardiac Dilatation Produce Pump Dysfunction?

Changes in pump function are best explained by the Frank-Starling relationship. Figure 1.2 illustrates the normal Frank-Starling relationship and the changes that occur in association with either an enhanced pump function or a decreased pump function. A left and upward shift of the curve compared to normal (an enhanced pump function) occurs when intrinsic myocardial contractility increases (such as in the presence of increased circulating catecholamines as may occur with exercise); or afterload decreases (such as following vasodilatation); or the relationship between wall thickness and internal radius increases (such as with compensatory cardiac hypertrophy). In contrast, displacement to the right and downward from the normal occurs when ventricular contractility is depressed; or afterload is increased; or the heart dilates as is the case in most forms of heart failure due to systolic functional abnormalities. Although the impact of changes in intrinsic myocardial contractility and the resistance to blood flow on systolic function, are relatively easy concepts to grasp, cardiac dilatation is sometimes a conceptually difficult issue. Hence, how does cardiac dilatation produce deleterious effects on pump function?

As chamber dilatation is associated with an increased cavity volume (and hence radius), and a reduced wall thickness, according to La Place’s law, wall tension or stress (afterload) will be increased. As wall stress determines myocardial oxygen consumption, the myocardial oxygen demand-to-supply ratio may be increased in a dilated ventricle, and a demand-to-supply mismatch may subsequently decrease cardiac contraction. However, when systolic function was measured using a stress (or load)-independent measure of pump function (end systolic elastance) in an animal model of congestive cardiac failure and pump dysfunction associated with massive cardiac dilatation (Norton et al., 2002), pump function was reduced without parallel changes in myocardial contractility. These data would suggest that a mechanism
Figure 1.2 Example of changes in the Frank-Starling relationship
unrelated to stress or load-induced effects contributes to pump dysfunction in cardiac dilatation. It is possible that inappropriate force transduction occurs in dilated ventricles during myocyte contraction, which in-turn leads to pump dysfunction (Sallin 1969). Alternatively, in a dilated ventricle, larger chamber volumes may be required to produce cardiomyocyte stretch and hence to recruit the Frank-Starling effect. Indeed, when the structure of the ventricle changes, the mechanics of systolic output are affected, thus resulting in a low-output state (Laskey et al., 1984; Cohn et al., 2000).

Having established that cardiac dilatation is a cause rather than a consequence of pump dysfunction and heart failure; in order to reduce morbidity or mortality from progressive heart failure treatments which prevent or reverse adverse cardiac remodelling are required. The choice of effective therapy is based on the knowledge of the mediators and the mechanisms responsible for cardiac remodelling. I will therefore discuss what is known to date regarding the mediators of cardiac dilatation and the role of various potential mechanisms.

1.2 MEDIATORS OF CARDIAC HYPERTROPHY AND ADVERSE CARDIAC REMODELLING

The generally accepted theory is that the mediators responsible for compensatory cardiac hypertrophy, when sustained are ultimately responsible for the progression to adverse cardiac remodelling and heart failure. I will therefore discuss what is known regarding the mediators of compensatory hypertrophy as well as the how these factors are thought to mediate cardiac dilatation and the development of heart failure.
Compensatory cardiac hypertrophy and cardiac dilatation occur due to the independent and interactive effects of three extrinsic mediators on the heart, namely: (1) neurohormones; (2) growth factors and inflammatory cytokines; and (3) mechanical stretch receptors in the cell membranes, which activate signalling pathways intracellularly (Cohn et al., 2000; Ferrari et al., 2009; Frigerio & Roubina, 2005; Remme 2003).

These extrinsic mediators act via various intracellular pathways [mitogen activated protein (MAP) kinase; nuclear factor κB; protein kinase B] to activate nuclear transcription, which leads to cellular hypertrophy, necrosis, apoptosis and fibrosis (Katz 2002; Opie et al., 2006; Yousef et al., 2000). The nature of the signalling stimulus is believed to determine which intracellular pathways are activated and hence whether compensatory cardiac hypertrophy or cardiac dilatation occurs (Ferrari et al., 2009; Hill & Olson 2008; Opie et al., 2006).

1.2.1 Role of Neurohormones in Compensatory Cardiac Hypertrophy and the Progression to Cardiac Decompensation and Heart Failure

Neurohormonal activation [activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS)] is known to occur in response to increases in cardiac wall stress. Indeed, circulating concentrations of noradrenaline are increased in persons with hypertension and LV hypertrophy (Agabiti-Rosei et al., 1987; Kelm et al., 1996). In addition, the RAAS is activated in the hypertrophied and failing heart (Danser et al., 1997; Iwai et al., 1995). Initially, the increased activity of the SNS and RAAS occur in order to normalise wall stress and to preserve contractile performance; however continual activation of the SNS (Badenhorst et al., 2003b; Gibbs et al., 2004; Veliotes et al., 2005) and
the RAAS (Mizuno et al., 2001; Schunkert et al., 1993) have been shown to induce cardiac dilatation and heart failure. Indeed, neurohumoral activation in heart failure (Hasking et al., 1986), is a major factor responsible for the progression of heart failure (Bristow 1997; Cohn et al., 1984).

1.2.1.1 Role of the Sympathetic Nervous System

Initially in compensatory hypertrophy, in response to increased catecholamines, the inotropy of the cardiac myocytes is increased through post receptor activation of adenylate cyclase and consequent increases in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). This response will improve the cardiac output through an increased myocardial contraction. However, sustained elevations in catechoamines in the presence of increased pressure loads will increase myocardial oxygen demand (a consequence of increased inotrope as well as increased afterload, due to alpha adrenergic mediated vasoconstriction), which may outstrip myocardial oxygen supply, as increased vascularisation does not occur in parallel with myocardial hypertrophy (Weisman et al., 1988). One of the consequences of oxygen demand-to-supply imbalance is tissue necrosis. As cardiac myocytes within the syncitium die, the viable cardiac myocytes within the syncitium are stretched hence possibly resulting in side-to-side slippage and ultimately cardiac dilatation (Figure 1.3). Indeed, myocyte slippage in end stage dilated cardiomyopathy has been well documented (Beltrami et al., 1995; Linzbach 1960).

Sustained (or chronic) activation of the SNS not only induces cardiac myocyte death through hemodynamic mechanisms as described above, but also via direct mechanisms. Indeed, excessive concentrations of adrenergic agonists promote necrosis (Esler et al., 1997) and apoptosis (Communal et al., 1998; Singh et al., 2001). Adrenergic-induced cardiac myocyte
Figure 1.3  Schematic representation showing possible mechanisms of cardiac dilatation.
apoptosis is mediated via activation of β1-adrenergic receptor cAMP-dependent protein kinase A and mitogen-activated protein kinase (MAPK) pathways. Adrenergic activation may also promote cardiomyocyte apoptosis indirectly via stimulation of the RAAS (see 1.2.1.2 below) or through increases in myocardial expression of inflammatory cytokines (see 1.2.2 below). Similar to necrosis the consequences of apoptosis are stretching of the viable cardiac myocytes within the syncitium are stretched hence possibly resulting in side-to-side slippage and ultimately cardiac dilatation (Figure 1.3). In addition to cardiac myocyte death, chronic β-adrenergic activation results in unfavourable alterations in the cardiac interstitium, which result in decreased tethering of the cardiac myocytes (Figure 1.3). Indeed, as will be discussed below (see 1.4.1) increases in the non-cross-linked collagen content of the myocardium have been demonstrated in association with cardiac dilatation after chronic administration of the β-adrenergic agonist isoproterenol (Woodiwiss et al., 2001). Although, isoproterenol, has been shown to stimulate the activity of matrix metalloproteinases (MMPs) in isolated cardiac myocytes (Coker et al., 2001), which would increase collagen turnover thereby reducing time available for cross-linking to occur (Woodiwiss et al., 2001); it is more likely that the changes in the characteristics of myocardial collagen are mediated by activation of the RAAS, as the decreased collagen cross-linking could be prevented by both angiotensin-converting enzyme inhibitor administration (Woodiwiss et al., 2001) as well as aldosterone receptor blockade (Veliotes et al., 2005).

Although, adrenergic activation, together with activation of inflammatory cytokines, has been associated with cardiac myocyte hypertrophy (increased cell width) (Tarone & Lembo, 2003); to date there is no evidence to implicate adrenergic activation in promoting lengthening of cardiac myocytes.
Evidence of the potential role of activation of the SNS in mediating adverse cardiac remodelling is provided by the detection of substantially increased plasma concentrations of noradrenaline and adrenaline in patients with heart failure (Anand et al., 2003; Cohn et al., 1984; Francis et al., 1993; Swedberg et al., 1990), and the relationship of these concentrations to the severity of pump dysfunction (Kluger et al., 1982) and heart failure (Sigurdsson et al., 1994). Furthermore, a number of studies have demonstrated that β-adrenergic receptor blocking agents reduce cardiac cavity dimensions (Gerson et al., 2002; Metra et al., 2003; Packer et al., 1996; Toyama et al., 2003; Waagstein et al., 1993a; Waagstein et al., 1993b).

1.2.1.2 Role of the Renin-Angiotensin-Aldosterone System

Initially activation of the RAAS is compensatory in nature in that RAAS mediated fluid retention improves venous return and thus cardiac output (via the Frank-Starling effect). However sustained elevations in the RAAS are detrimental. Indeed, both angiotensin II and aldosterone have been shown to promote cardiac myocyte apoptosis (De Angelis et al., 2002), and hence the potential for side-to-side slippage of cardiac myocytes (Figure 1.3).

Activation of the RAAS is also likely to play a role in the unfavourable changes in the characteristics of myocardial collagen, as decreased collagen cross-linking associated with cardiac dilatation could be prevented by both angiotensin-converting enzyme inhibitor administration (Woodiwiss et al., 2001) as well as aldosterone receptor blockade (Veliotes et al., 2005). In addition, angiotensin II and aldosterone have been shown to stimulate collagen synthesis (Brilla et al., 1994).

Although, angiotensin II acting as a growth factor has been shown to mediate cardiac
myocyte hypertrophy by increasing cell width (Sadoshima et al., 1997; Serneri et al., 1999), the role of the RAAS in cardiac myocyte lengthening is as yet unclear.

Nevertheless, the role of the RAAS in adverse cardiac remodelling is substantiated by intervention data showing reductions in cardiac dimensions following the administration of ACEI to patients in heart failure (Greenberg et al., 1995; Konstam et al., 1992).

### 1.2.2 Role of Growth Factors and Inflammatory Cytokines

Growth factors such as insulin-like growth factor are thought to mediate cellular hypertrophy via the protein kinase B pathway (Opie et al., 2006). Activation of this pathway promotes cardiac myocyte growth (increased cell width) and inhibits apoptosis (Matsui & Rosenzweig, 2005). Hence, activation of insulin-like growth factor is important in mediating compensatory hypertrophy, but possibly plays no role in the transition to cardiac decompensation. In comparison transforming growth factor β, similar to angiotensin II, activates fibroblasts hence promoting collagen formation and fibrosis (Hein et al., 2003; Kuwahara et al., 2004). Increased fibrosis (as discussed below) is important in both compensatory hypertrophy and dilatation. Inflammatory cytokines, such as tumour necrosis factor α, seem to have a dual role. At low concentrations these cytokines mediate compensatory hypertrophy; whereas at high concentrations they may play a role in mediating cardiac dilatation and heart failure (Tarone & Lembo, 2003). Lastly, cardiac myocyte apoptosis may be promoted by increased myocardial expression of inflammatory cytokines as a consequence of adrenergic activation (Baumgarten et al., 2000). However, intervention studies targeting inflammatory cytokines proved disappointing in patients with heart failure, in that no differences were observed in rates of death or hospitalisation due to chronic heart failure compared to placebo (Anker & Coats 2002).
1.2.3 Role of Stretch Receptors (Cardiac Myocyte Stretch)

The hypertrophy of cardiac myocytes is also regulated by stretch mediated by hemodynamic loading conditions (Russell et al., 2010); in association with increased activation of the RAAS (Kudoh et al., 1997; Sadoshima et al., 1993. In this regard increases in ventricular volume (increased diastolic strain) are thought to be responsible for increases in cardiac myocyte length (Russell et al., 2010); whereas increases in pressure (increased systolic stress) produce increases in cardiac myocyte width (Russell et al., 2010). Consequently, compensated cardiac hypertrophy is associated with increases in cardiac myocyte width and cross-sectional area in proportion to increases in length (Onodera et al., 1998; Zierhut et al., 1991). In comparison, in the decompensated state, changes in cardiac myocyte length may exceed increments in cardiac myocyte width (Fedak et al., 2005; Gerdes & Capasso 1995).

1.3 PROPOSED MECHANISMS OF COMPENSATORY CARDIAC HYPERTROPHY

Mechanisms of compensatory cardiac hypertrophy include changes in the cardiac interstitium as well as changes in the cardiac myocytes. In essence compensatory cardiac hypertrophy is associated with increased cardiac interstitial fibrosis, increased collagen cross-linking, as well as cardiac myocyte hypertrophy (increased cell width). These mechanisms will be discussed separately below.

1.3.1 Role of Collagen and Interstitial Changes

In compensatory cardiac hypertrophy, in response to increased angiotensin II, aldosterone, transforming growth factor β and noradrenaline, cardiac fibroblasts are activated (Hein et al.,
2003; Kuwahara et al., 2004; Weber et al., 1990; Weber et al., 1993). Consequently, collagen synthesis is enhanced. In addition, matrix metalloproteinases (MMPs), which are responsible for collagen degradation (Gunasinghe et al., 2001) are inhibited (Janicki et al., 2004), hence collagen deposition exceeds collagen degradation. In addition, compensatory hypertrophy is associated with increased collagen cross-linking, mediated by increased activity of the cross-linking enzyme lysyl oxidase (Hermida et al., 2009). As a consequence of increased fibrosis and collagen cross-linking, there is adequate tethering of cardiac myocytes to the interstitial matrix. Hence in the presence of increased loading conditions the structural morphology of the cardiac chamber is maintained.

1.3.2 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell Width

The initial response to high pressures in the cardiovascular system is cellular hypertrophy by means of increases in cardiac myocyte width, which result in increases in chamber wall thickness (Grossman et al., 1975). In response to increased afterload (increased cardiac wall stress due to high pressures in the cardiovascular system), cardiac hypertrophy occurs in order to increase cardiac wall thickness and hence to decrease cardiac wall stress (via La Place’s law) (Grossman et al., 1975). In addition, cellular hypertrophy occurs in an attempt to relieve the heart of the raised filling pressures (increased preload) by increasing the output of the heart through an increased stroke volume or systolic function. The greater stroke volume is achieved by the increased muscle mass which generates a stronger muscle force. Katz et al. (2002), in a review article, refer to this process of hypertrophy by the heart and its myocytes as an attempt to ‘grow their way out of trouble’. In other words, in the presence of increased loading conditions, the ventricles need to grow (through hypertrophy) in order to reduce the loading conditions.
The initial response of cardiac muscle tissue to increased pressure load conditions is to increase cardiac myocyte width through parallel additions of cardiac myofilaments (Onodera et al., 1998; Zierhut et al., 1991), thus resulting in thickening of the myocardial wall. In models of pressure overload (hypertension), both Onodera et al. 1998 and Zierhut et al. 1991, showed that initially cardiac hypertrophy was accompanied by increases in cardiac myocyte width but not by changes in cardiac myocyte length. Hence, the initial response of the cardiac myocyte to augmented afterload is to increase in width but not in length (Onodera et al., 1998; Zierhut et al., 1991). As a consequence of increases in cardiac wall thickness subsequent to cellular hypertrophy, the luminal radius is reduced (Janicki et al., 2004). An increase in the width of the ventricular wall with a concomitant reduction in the luminal radius is commonly referred to as concentric or compensatory hypertrophy (Janicki et al., 2004). This initial form of hypertrophy in response to increased cardiovascular loading conditions is considered compensatory in nature (Janicki et al., 2004).

1.4 PROPOSED MECHANISMS OF ADVERSE CARDIAC REMODELING

The mechanisms by which the cardiac tissue remodels to cause the dilatation are the topic of much debate. However, as with compensatory cardiac hypertrophy both changes in the cardiac interstitium as well as changes in the cardiac myocytes are believed to play a role. In essence adverse cardiac remodelling is associated with increased cardiac interstitial fibrosis, but of the non-cross-linked form; cardiac myocyte apoptosis and necrosis; as well as cardiac myocyte hypertrophy due to changes in cell length. These mechanisms will be discussed separately below.
1.4.1 Role of Collagen and Interstitial Changes

Sustained elevations in noradrenaline, angiotensin II, aldosterone and transforming growth factor β increase collagen synthesis (Boluyt et al., 1995; Hein et al., 2003; Weber & Brilla 1991; Weber et al., 1993). However, sustained elevations in these neurohormones are also accompanied by increases in MMP activity (Banfi et al., 2005; Mujundar & Tyagi, 1999; Spinale et al., 1998). Therefore, both collagen synthesis and degradation are enhanced. Indeed, reductions in cardiac chamber dimensions following the use of LV assist devices are generally accompanied by increases rather than decreases in myocardial collagen concentrations (Li et al., 2001; Scheinin et al., 1992); whereas pacing-induced cardiac dilatation (Spinale et al., 1991) and adrenergic-induced cardiac dilatation (Woodiwiss et al., 2001) are accompanied by decreases in myocardial collagen concentrations. Hence, alterations in the characteristics of myocardial collagen, rather than in myocardial collagen concentrations, are more likely to contribute toward chamber dilatation.

As a consequence of enhanced collagen turnover (increased synthesis and degradation), the time available for collagen cross-linking to occur is decreased (Woodiwiss et al., 2001). A reduction in collagen cross-linking reduces the capacity to tether cardiac myocytes (Li et al., 2001; Mann & Spinale 1998), resulting in side-to-side slippage of cardiac myocytes and hence the development of cardiac dilatation (Olivetti et al., 1990; Woodiwiss et al., 2001) (Figure 1.3). Indeed, non cross-linked collagen is associated with cardiac dilatation and systolic dysfunction (Capasso et al., 1989; Gunja-Smith et al., 1996; Spinale et al., 1996; Woodiwiss et al., 2001).

In addition, non cross-linked collagen may be more susceptible to degradation by MMPs thus resulting in decreased tethering of cardiac myocytes and cardiac dilatation (Badenhorst et al.,
Indeed, genetic decreases in the susceptibility of collagen to degradation, reduce the degree of dilatation which accompanies pressure-overload states (Papadimitriou et al., 1974). In addition, increased myocardial expression and activation of MMPs has been demonstrated in patients with heart failure or in patients with a reduced systolic function and cardiac dilatation (Li et al., 2001; Polyakova et al., 2004; Reddy et al., 2004; Spinale et al., 2000; Spinale, 2002), and in animal models of pump dysfunction and cardiac dilatation (King et al., 2003; Mukherjee et al., 2003; Peterson et al., 2001; Rohde et al., 1999; Sakata et al., 2004; Spinale et al., 1998). Moreover, MMP inhibition attenuates left ventricular dilatation in animal models of pacing-induced heart failure (Spinale et al., 1999), myocardial infarction (Mukherjee et al., 2003; Rohde et al., 1999) and heart failure in the spontaneously hypertensive rat (Peterson et al., 2001); and a loss of MMP inhibitory control of MMPs, through a gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1), has been demonstrated to lead to ventricular dilatation in mice (Roten et al., 2000).

1.4.2 Role of Cardiac Myocyte Apoptosis and Necrosis

Cardiac myocyte cell death may occur via an active, regulated, energy demanding process controlled by an inherited genetic program (Sabbah & Sharov, 1998) resulting in apoptosis. Alternatively cardiac myocyte death may occur via the unregulated process of necrosis (Kang & Izumo, 2000). Due to sustained increases in noradrenaline and angiotensin II, and the consequence of myocardial oxygen demand exceeding supply, necrosis and apoptosis of cardiac myocytes occurs. Cardiac myocyte death could reduce the capacity to tether cardiac myocytes hence promoting side-to-side slippage of cardiac myocytes (Figure 1.3). Hence, cardiac myocyte death mediated either by tissue apoptosis or necrosis may promote the development of cardiac dilatation (Yussman et al., 2002). Indeed, cardiac dilatation occurs
following myocardial infarction and cellular necrosis (Anversa et al., 1985; Zimmer et al., 1990; Olivetti et al., 1990).

1.4.3 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell Length

Although, cardiac dilatation is thought to be mediated by increases in the length of cardiac myocytes, not all studies support this hypothesis. Indeed, although some studies show that increases in cardiac myocyte length are associated with increases in cardiac chamber dimensions or heart failure (Beltrami et al., 1994; Gerdes et al., 1996; Gerdes et al., 2010; Janczewski et al., 2003; Kajstura et al., 1995; Pangonyte et al., 2008; Schultz et al., 2007; Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999; Zefeiridis et al., 1998); a number of other studies show no relationship (Li et al., 2010; Schultz et al., 2007; Tamura et al., 2000; Yarbrough et al., 2010). Furthermore, data from intervention studies failed to show changes in cardiac dimensions in parallel with changes in cardiac myocyte length (Kuzman et al., 2007; Li et al., 2010; Schultz et al., 2007; Tamura et al., 2000). Therefore, it is important to discuss possible reasons for the controversial results regarding the possible role of alterations in cardiac myocyte length in cardiac dilatation.

1.4.3.1 Are Changes in Cardiac Dimensions Associated with Changes in Cardiac Myocyte Length?

1.4.3.1.1 Data From Human Studies:

Previous data obtained in human studies on the possible association between cardiac myocyte length and cardiac dimensions are summarised in Table 1. The data from human studies indicate that increases in cardiac myocyte length accompany increases in cardiac chamber
Table 1.1: Summary of human data addressing possible association of cardiac remodelling with alterations in myocyte morphology

<table>
<thead>
<tr>
<th>Pathology/Model/Intervention</th>
<th>Measure of Cardiac Remodeling</th>
<th>Function / Presence of Heart Failure</th>
<th>Method of Cardiac Assessment</th>
<th>Myocyte Morphology</th>
<th>Method of Cell Measurement</th>
<th>Reference</th>
<th>My Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac transplantation in patients with congestive heart failure due to ischemic cardiomyopathy (males)</td>
<td>↑ transverse chamber diameter</td>
<td>Patients with congestive HF</td>
<td>Anatomical measurement</td>
<td>↑ length</td>
<td>Measurement of cells in histological sections</td>
<td>Beltrami et al 1994</td>
<td>↑ LVEDD associated with ↑ cell length in patients in HF, but assessments all anatomical</td>
</tr>
<tr>
<td>Cardiac transplantation in patients with congestive heart failure due to ischemic cardiomyopathy (males)</td>
<td>Not done</td>
<td>↓ EF (in vivo)</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>↑ length</td>
<td></td>
<td>Gerdes et al 1992</td>
<td>↓ EF associated with ↑ cell length, but no LV dimension data. All patients were male &amp; had higher body weight than controls (all females), hence ↑ cell length may be due to ↑ body weight and therefore ↑ heart weight in patients</td>
</tr>
<tr>
<td>Cardiac transplantation in patients with heart failure (12 ischemic &amp; 18 nonischemic) (80% males versus 50% males in control group)</td>
<td>↑ LVEDD Normalisation of LVEDD</td>
<td>↑ PCWP Normalisation of PCWP</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>↑ length</td>
<td></td>
<td>Zafeiridis et al 1998</td>
<td>↑ LVEDD associated with ↑ cell length, but ↑ LVEDD is a preload induced effect (↑ PCWP). More patients were male &amp; hence had higher body weight than controls, therefore ↑ cell length may be due to ↑ body weight and therefore ↑ heart weight in patients</td>
</tr>
<tr>
<td>LV assist device support in 10 patients with heart failure (80% males)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 12 hours of MI in patients who died from first MI compared with patients who died after second or subsequent MI (males)</td>
<td>↑ endocardial surface area</td>
<td>No clinical symptoms of HF</td>
<td>Anatomical measurement</td>
<td>↑ length in both MI groups</td>
<td>Measurement of cells in histological sections</td>
<td>Pangonyte et al 2008</td>
<td>↑ cell length occurs during ischaemia and prior to MI and development of HF</td>
</tr>
</tbody>
</table>

↑, increase; ↓, decrease; echo, echocardiography; EF, ejection fraction; HF, heart failure; LV, left ventricle; LVEDD, left ventricular end diastolic diameter; PCWP, pulmonary capillary wedge pressure; ↑, ↓ and no change are in comparison to control group unless otherwise stated
diameter (Beltrami et al., 1994; Pangonyte et al., 2008; Zefeiridis et al., 1998). However, it would be incorrect to draw a conclusion that adverse chamber remodelling (cardiac dilatation) is associated with increases in cardiac myocyte length, from this data for a number of reasons.

Firstly, in one these studies (Zefeiridis et al., 1998), echocardiography in vivo was used to determine left ventricular end diastolic diameters and hence the cardiac chamber dimension measurements were load dependent. As increases in pulmonary capillary wedge pressure were noted in the patients in this study (Zefeiridis et al., 1998), the increased chamber dimensions are likely to be due to increases in LV preload. In this regard, as discussed previously, cardiac myocyte lengthening occurs as a consequence of the stretching of cardiac myocytes during increased preloads (Ferrari et al., 2009). Indeed, Zefeiridis et al. (1998) showed a normalisation of both LV end diastolic diameter and cardiac myocyte length, when pulmonary capillary wedge pressure was normalised as a consequence of LV assist device support. Left ventricular assist devices divert blood from the left atrium to the aorta, thereby removing the preload and afterload to the left ventricle. Hence these devices are used to provide haemodynamic support for patients with end-stage heart failure awaiting transplantation.

Secondly, in the study of Beltrami et al. (1994), the hearts were collected at autopsy for the control group and during cardiac transplantation for the heart failure group. Measurements of cardiac chamber dimensions and cardiac myocyte length were made anatomically; however no mention was made as to whether the hearts were arrested in diastole or systole. It is possible that during transplantation the hearts were arrested in diastole, as this was part of the surgical procedure at the time; whereas in the control group the phase of the cardiac cycle at the time of arrest was unknown as 70% of the control hearts were obtained from individuals in whom death was sudden due to traumatic injury. As the phase of the cardiac cycle
determines cardiac chamber dimensions and cardiac myocyte length, possible differences between the heart failure and control groups in the phase of the cardiac cycle at the time of cardiac arrest may have accounted for the differences in cardiac chamber diameter and cardiac myocyte length between these two groups.

Thirdly, in some studies the increased cardiac myocyte length in patients compared to controls could be as a consequence of the differences in body weight and hence LV weight between these two groups (Gerdes et al., 1992; Zafeiridis et al., 1998). Indeed, in one study all patients in heart failure were males; whereas all healthy controls were females (Gerdes et al., 1992). As the males had greater body weights than the controls (Gerdes et al., 1992), the increased cardiac myocyte length may be attributed to the greater body size in the males rather than to the presence of heart failure. Similarly, in another study the increased cardiac myocyte length in the patients compared to the controls may in part be attributed to the greater proportion of males in the heart failure group compared to the control group (Zafeiridis et al., 1998).

Lastly, in a study assessing cardiac myocyte length and cardiac dimensions within 12 hours of death due to a first myocardial infarction compared to within 12 hours of death from a second or subsequent myocardial infarction, increases in cardiac myocyte length were noted in both groups with myocardial infarction compared to a control group who died from non-cardiovascular causes (Pangonyte et al., 2008). Importantly neither of the myocardial infarction groups had clinical symptoms of heart failure. Therefore, from this study it can be concluded that increases in cardiac myocyte length occur during ischaemia before myocardial infarction and the development of heart failure.

Hence, from human studies published to date, the potential relationship between adverse chamber remodelling (cardiac dilatation) and cardiac myocyte length is unclear.
1.4.3.1.2 Data from Animal Experimental Models:

Previous data on the possible association between cardiac myocyte length and cardiac dimensions obtained from animal experimental models are summarised in Table 2. Although a number of studies have attempted to address the question of the relationship between cardiac myocyte length and cardiac dimensions in various animal experimental models; the data is controversial. Some studies show that increases in cardiac myocyte length are associated with increases in cardiac chamber dimensions or heart failure (Gerdes et al., 1996; Gerdes et al., 2010; Janczewski et al., 2003; Kajstura et al., 1995; Schultz et al., 2007; Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999); whereas a number of other studies show no relationship (Li et al., 2010; Schultz et al., 2007; Tamura et al., 2000; Yarbrough et al., 2010). As with the human studies, a number of possible reasons may explain the controversial data.

One of the reasons for the contrasting findings is the use of load dependent measures of cardiac chamber dimensions (echocardiography in vivo) in the presence of increased preloads (Chen et al., 2010; Gerdes et al., 2010; Kajstura et al., 1995; Tamura et al., 1998; Wang et al., 1999; Yarbrough et al., 2010). As discussed above with respect to human studies, the increased cardiac chamber diameters and cardiac myocyte length noted in these studies may be indicative of the increased preloads rather than the presence of adverse chamber remodelling (cardiac dilatation).

Secondly, in a number of studies showing an association between cardiac myocyte length and cardiac chamber dimension, the experimental animals (spontaneously hypertensive heart failure, SHHF rats) were from 12 to 16 months older than the control animals (Gerdes et al., 1996; Tamura et al., 1998). As LV weight increases with age in hypertensive rats (Gerdes et
Table 1.2: Summary of data from animal experimental models addressing possible association of cardiac remodelling with alterations in myocyte morphology

<table>
<thead>
<tr>
<th>Pathology/Model/Intervention</th>
<th>Measure of Cardiac Remodeling</th>
<th>Function / Presence of Heart Failure</th>
<th>Method of Cardiac Assessment</th>
<th>Myocyte Morphology</th>
<th>Method of Cell Measurement</th>
<th>Reference</th>
<th>My Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dogs with pacing-induced heart failure (gender not stated)</td>
<td>↑ chamber diameter</td>
<td>↑ LVEDP, ↓ LVSP</td>
<td>LV dimensions of cardiac rings following perfusion fixation at LVEDP measured \textit{in vivo}</td>
<td>↑ length</td>
<td>Direct measurement of freshly isolated myocytes</td>
<td>Kajstura et al. 1995</td>
<td>As ↑ LVEDP in dogs with pacing-induced HF, ↑ LV dimensions likely to be due to ↑ preload</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats genetically predisposed to developing heart failure with increasing age (spontaneously hypertensive heart failure, SHHF) (females)</td>
<td>Not done</td>
<td>Clinical signs of HF (dyspnoea, cyanosis), ↑ liver weight, ↑ lung wet weight, ↓ LV systolic pressure</td>
<td>Catheter plus pressure transducer \textit{(in vivo)}</td>
<td>↑ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Gerdes et al. 1996</td>
<td>↑ cell length in rats in HF, but these rats were 12 months older than rats not in HF. As cardiac myocyte length is strongly correlated with age &amp; LV weight, and LV weight ↑ with age in hypertensive rats; ↑ cell length possibly due to ↑ age &amp; LV weight rather than ↑ LV dimensions</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats genetically predisposed to developing heart failure with increasing age (spontaneously hypertensive heart failure, SHHF) (females)</td>
<td>Not done</td>
<td>No clinical signs of HF</td>
<td>\textit{Echo (in vivo)}</td>
<td>↑ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Onodera et al. 1998 (Gerdes laboratory)</td>
<td>↑ cell length with age associated with ↑ heart weight/body weight with age in hypertensive rats without HF; therefore ↑ cell length possibly due to ↑ age &amp; heart weight rather than ↑ LV dimensions</td>
</tr>
<tr>
<td>Pathology/Model/Intervention</td>
<td>Measure of Cardiac Remodeling</td>
<td>Function / Presence of Heart Failure</td>
<td>Method of Cardiac Assessment</td>
<td>Myocyte Morphology</td>
<td>Method of Cell Measurement</td>
<td>Reference</td>
<td>My Interpretation</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------</td>
<td>------------------------------------</td>
<td>------------------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
<td>-----------</td>
<td>------------------</td>
</tr>
<tr>
<td>Rats genetically predisposed to developing heart failure with increasing age (spontaneously hypertensive heart failure, SHHF) (females)</td>
<td>↑ chamber circumference</td>
<td>Clinical signs of HF (eg. dyspnoea, ascites, pleural effusion, pericardial effusion, cyanosis)</td>
<td>Anatomical measurement of chamber circumference in formalin fixed heart slices</td>
<td>↑ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes &amp; myocytes isolated from formalin fixed tissue using potassium hydroxide</td>
<td>Tamura et al. 1998 (Gerdes laboratory)</td>
<td>↑ cell length in rats in HF, but these rats were 16 months older than rats not in HF. As cardiac myocyte length is strongly correlated with age &amp; LV weight, and LV weight ↑ with age in hypertensive rats; ↑ cell length possibly due to ↑ age &amp; LV weight rather than ↑ LV dimensions</td>
</tr>
<tr>
<td>Constriction of thoracic aorta in guinea pigs (males)</td>
<td>↑ LVEDD</td>
<td>↓ FS, ↓ EF, ↑ LVEDP</td>
<td>Echo (in vivo)</td>
<td>↑ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Wang et al 1999 (Gerdes laboratory)</td>
<td>As ↑ LVEDP in guinea pigs with ↓ FS &amp; ↓ EF, ↑ LVEDD likely to be due to ↑ preload</td>
</tr>
<tr>
<td>Rats genetically predisposed to developing heart failure with increasing age (spontaneously hypertensive heart failure, SHHF) (females)</td>
<td>↑ LVEDD at 22 months</td>
<td>No change in FS</td>
<td>No change in LVEDD</td>
<td>Echo (in vivo)</td>
<td>No change in length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Tamura et al. 2000 (Gerdes laboratory)</td>
</tr>
<tr>
<td>Angiotensin II type 1 receptor blocker administration to SHHF (females)</td>
<td>No change in LVEDD</td>
<td>No change in FS</td>
<td>No change in FS</td>
<td>Echo (in vivo)</td>
<td>↓ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td></td>
</tr>
<tr>
<td>Pathology/Model/Intervention</td>
<td>Measure of Cardiac Remodeling</td>
<td>Function / Presence of Heart Failure</td>
<td>Method of Cardiac Assessment</td>
<td>Myocyte Morphology</td>
<td>Method of Cell Measurement</td>
<td>Reference</td>
<td>My Interpretation</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>-------------------------------------</td>
<td>------------------------------</td>
<td>--------------------</td>
<td>--------------------------</td>
<td>-----------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Transgenic mice with cardiac specific overexpression of tumour necrosis alpha (results in the development of HF) (males compared to females)</td>
<td>↑ LVEDD only in males</td>
<td>↓ FS</td>
<td>Echo (in vivo)</td>
<td>↑ length in males &amp; females</td>
<td>Direct measurement of freshly isolated myocytes</td>
<td>Janczewski et al 2003</td>
<td>In females, ↑ cell length but no change in LVEDD, hence ↑ cell length not associated with ↑ LVEDD</td>
</tr>
<tr>
<td>Cardiomyopathic hamsters (male) L-thyroine administration Diodothyropropionic acid (thyroid hormone analogue) administration</td>
<td>↑ LVEDD</td>
<td>↓ EF</td>
<td>Echo (in vivo)</td>
<td>No change in length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Kucman et al 2007 (Gerdes laboratory)</td>
<td>Cell length not associated with LVEDD</td>
</tr>
<tr>
<td>Spontaneously hypertensive heart failure (SHHF) adult rats (females) Long-term exercise (16 months) in SHHF adult rats</td>
<td>↑ LVEDD</td>
<td>↓ EF &amp; ↓ FS</td>
<td>(in vivo); catheter plus pressure transducer (in vivo)</td>
<td>↑ length, but not different from non-exercise SHHF</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Schultz et al 2007 (Gerdes laboratory)</td>
<td>Despite greater ↑ LVEDD, ↓ EF, ↓ FS &amp; presence of ascites, no difference in cell length compared to non-exercise SHHF</td>
</tr>
<tr>
<td>Myocardial infarction (MI) via left coronary artery ligation in adult rats (males compared to females)</td>
<td>↑ LVEDD</td>
<td>↓ FS &amp; ↓ LV systolic pressure; ↑ LVEDP</td>
<td>Echo (in vivo); catheter plus pressure transducer (in vivo)</td>
<td>↑ length</td>
<td>Direct measurement of gluteraldehyde fixed freshly isolated myocytes</td>
<td>Chen et al 2010 (Gerdes laboratory)</td>
<td>↑ LVEDD, ↓ FS, ↓ LVSP &amp; ↑ LVEDP associated with ↑ cell length; but ↑ LVEDD is a likely to be a preload induced effect</td>
</tr>
<tr>
<td>Myocardial infarction (MI) via left coronary artery ligation in adult mice (males)</td>
<td>↑ LVEDD</td>
<td>↓ FS</td>
<td>Echo (in vivo)</td>
<td>No change in length</td>
<td>Direct measurement of freshly isolated myocytes</td>
<td>Li et al 2010</td>
<td>↑ LVEDD not associated with ↑ cell length</td>
</tr>
</tbody>
</table>

LVEDD: Left Ventricular End Diastolic Dimension; EF: Ejection Fraction; LVSP: Left Ventricular Systolic Pressure; LVEDP: Left Ventricular End Diastolic Pressure.
<table>
<thead>
<tr>
<th>Pathology/Model/Intervention</th>
<th>Measure of Cardiac Remodeling</th>
<th>Function / Presence of Heart Failure</th>
<th>Method of Cardiac Assessment</th>
<th>Myocyte Morphology</th>
<th>Method of Cell Measurement</th>
<th>Reference</th>
<th>My Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intramyocardial delivery of mesenchymal stem cells to mice with MI</td>
<td>Prevention of ↑ LVEDD</td>
<td>Prevention of ↓ FS</td>
<td>Echo (in vivo)</td>
<td>↑ length</td>
<td>Direct measurement of freshly isolated myocytes</td>
<td>Li et al 2010</td>
<td>Normalisation of LVEDD associated with ↑ cell length</td>
</tr>
<tr>
<td>↑ preload via aortocaval shunt in adult mice (females)</td>
<td>↑ LVEDD</td>
<td>No change in FS</td>
<td>Echo (in vivo)</td>
<td>↑ length</td>
<td>Direct measurement of freshly isolated myocytes</td>
<td>Toischer et al 2010</td>
<td>↑ cell length prior to ↓ FS</td>
</tr>
<tr>
<td>MI via ligation of circumflex coronary artery in adult pigs (gender not stated)</td>
<td>↑ LVEDD</td>
<td>↑ LVEDD, but &lt; in absence of caspase inhibition</td>
<td>↑ LVEDP</td>
<td>No change in length</td>
<td>Direct measurement of myocytes from formalin-fixed tissue</td>
<td>Yarbrough et al 2010</td>
<td>↑ LVEDD &amp; in HF (↑ LVEDP) but no change in cell length</td>
</tr>
<tr>
<td>Caspase inhibition to pigs with MI</td>
<td></td>
<td></td>
<td></td>
<td>No change in length</td>
<td></td>
<td></td>
<td>↑ LVEDD &amp; in HF (↑ LVEDP) but ↓ cell length</td>
</tr>
</tbody>
</table>

↑, increase; ↓ decrease; echo, echocardiography; EF, ejection fraction; FS, fractional shortening; HF, heart failure; LV, left ventricle; LVEDD, left ventricular end diastolic diameter; LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure; PCWP, pulmonary capillary wedge pressure; PWTd, posterior wall thickness in diastole; SHHF, spontaneously hypertensive heart failure; ↑, ↓ and no change are in comparison to control group unless otherwise stated.
al. 1996), and cardiac myocyte length is strongly associated with age in SHHF rats (Tamura et al., 1998) and with LV weight (Campbell et al. 1991; Capasso et al. 1992), the increases in cardiac myocyte length observed in the experimental groups may reflect age induced changes, rather than an association with adverse chamber remodelling (cardiac dilatation) and the development of heart failure.

Thirdly, data from various intervention studies failed to show changes in cardiac dimensions in parallel with changes in cardiac myocyte length. In intervention studies where increases in cardiac chamber diameter were prevented by thyroid hormone administration (Kuzman et al., 2007) or intramyocardial delivery of mesenchymal stem cells (Li et al., 2010), either no change (Kuzman et al., 2007) or even increases in cardiac myocyte length (Li et al., 2010) were noted. Alternatively, in one study decreases in cardiac myocyte length were noted subsequent to angiotensin II receptor blockade, but no changes in cardiac chamber dimensions were noted (Tamura et al., 2000). Furthermore, in a study of the effects of long-term exercise in rats with heart failure, further increases in cardiac chamber dimensions due to exercise training were not accompanied by further increases in cardiac myocyte length (Schultz et al., 2007). The results from the intervention studies discussed above, although different from each other, do not show parallel changes in cardiac chamber dimensions and cardiac myocyte length. Therefore the results of these studies do not support a role of changes in cardiac myocyte length in cardiac dilatation. Indeed, if increases in cardiac myocyte length were causally related to adverse cardiac remodelling, a reduction in cardiac myocyte length should be accompanied by a decrease in cardiac chamber dimensions. Hence the data provides no clear conclusion as to the possible role of cardiac myocyte length in adverse chamber remodelling. In fact, it could be concluded that there is no causal relationship.
However, the data need to be interpreted with caution in view of the use of load dependent measures of cardiac dimensions in these studies.

Lastly, few studies have made direct comparisons of animals with cardiac pathology which have heart failure to animals with the same cardiac pathology but without heart failure. The only studies which have used this study design have been done in SHHF rats (Gerdes et al., 1996; Tamura et al., 1998 and 2000). However, in these studies the rats in heart failure were from 12 to 22 months older than the rats not in heart failure. As discussed above, as cardiac myocyte length is associated with age (Tamura et al., 1998), the increased cardiac myocyte length may reflect increased age rather than increased cardiac dimensions. Indeed, a study by Onodera et al. (1998) showed that cardiac myocyte lengthening increased with age and occurred well before the development of heart failure in SHHF rats. Although the study by Onodera et al. (1998) suggests that changes in cardiac myocyte length are not responsible for the development of heart failure, no measurements of cardiac dimensions were made in this study. To my knowledge no study to date has compared age-matched animals with the same cardiac pathology which have heart failure to those without heart failure.

Hence the data obtained from animal experimental models to date are equally confusing and hence the question of the relationship between cardiac myocyte length and adverse cardiac chamber remodelling remains unresolved.

1.5 PROBLEM STATEMENT AND STUDY OBJECTIVES

In summary, despite a plethora of studies aimed to address the relationship between cardiac dimensions and cardiac myocyte length, to date the data are controversial (Tables 1.1 and 1.2,
and Figure 1.4). As discussed the data are limited by the use of load dependent measures of cardiac dimensions; the comparison of hearts from humans of different gender and body size; the comparison of hearts from rat groups of different age and body size; and a failure to make direct comparisons between age-matched animals with cardiac pathology who are in heart failure and those who are not in heart failure. Hence, the role of cardiac myocyte length in adverse cardiac remodelling needs to defined using load independent measures of chamber dimensions and in age-matched animals where direct comparisons are made between animals with cardiac pathology who are in heart failure and those who are not in heart failure.

To address the limitations discussed above, I chose to study two models of cardiac dilatation in pressure-overload induced cardiac hypertrophy in rats. The first model of cardiac dilatation was a **natural progression model** in that it involved the use of 23 month old SHR. In SHR older than 21 months of age, left ventricular hypertrophy is noted to progress to left ventricular decompensation, dilatation and heart failure in approximately half of the rats (Bing et al. 1995; Norton et al. 1997; Tsotetsi et al. 2001). The second model of cardiac dilatation, a **pharmacological model**, was induced in 14 month old SHR by chronic beta-adrenoreceptor activation [daily administration of the beta-adrenergic agonist isoproterenol (ISO) for a period of 4.5 months]. Chronic beta-adrenoreceptor activation in SHR, has been shown enhance the progression from compensated left ventricular hypertrophy to left ventricular dilatation (Badenhorst et al. 2003b; Gibbs et al. 2004). In both of these models the rats in heart failure were age-matched to the rats not in heart failure and comparisons were made with an age-matched healthy control group. Importantly, in my studies I used load independent measures (determination of filling pressures at controlled volumes) to define cardiac dilatation.
Figure 1.4  Schematic representation of the factors known to contribute to cardiac dilatation; whereas the role of cardiac myocyte lengthening is still controversial.
The studies in this dissertation aimed to determine the role that cardiac myocyte lengthening in the development of adverse chamber remodelling (cardiac dilatation) that occurs in pressure-overload states in rats.

The specific objectives of my studies were:

- to compare the length of cardiac myocytes isolated from SHR rats in heart failure to those isolated from SHR rats without heart failure (natural progression model)
- to compare the length of cardiac myocytes isolated from SHR rats receiving isoproterenol (rats in heart failure) to those isolated from SHR rats not receiving isoproterenol (rats without heart failure) (pharmacological model)
- to compare the cardiac dimensions (measured using load independent measures), of SHR rats in heart failure to those isolated from SHR rats without heart failure (natural progression model)
- to compare the cardiac dimensions (measured using load independent measures), of SHR rats receiving isoproterenol (rats in heart failure) to those isolated from SHR rats not receiving isoproterenol (rats without heart failure) (pharmacological model)
- to determine the relationship between cardiac myocyte length and cardiac dimensions measured using load independent measures (both natural progression model and pharmacological model)
CHAPTER 2
2. METHODS

In order to assess the role that changes in cardiac myocyte dimensions have on the development of dilatation, two models of cardiac dilatation in pressure-overload induced cardiac hypertrophy in rats were used. All studies in this dissertation were approved by the Animal Ethics Screening Committee (AESC) of the University of the Witwatersrand (AESC Clearance Numbers 1997:44:5; 1999:01:2b; 2002:37:5; 2002:39:5 & 2006:41:5). The rats were obtained from the Central Animal Services (CAS) Unit of the University of the Witwatersrand, Johannesburg, South Africa.

2.1 RAT STRAINS AND GROUPS

For both models of cardiac dilatation in pressure-overload induced cardiac hypertrophy, I used spontaneously hypertensive rats (SHR), which are a strain of rats bred to have increased blood pressures (Gerdes et al. 1996; Tamura et al. 1998; Tsotetsi et al. 2001). As a consequence of chronically elevated blood pressures, SHR develop left ventricular hypertrophy after 11 months of age (Norton et al. 1997). The first model of cardiac dilatation was a natural progression model in that it involved the use of 23 month old SHR (n=18). In SHR older than 21 months of age, left ventricular hypertrophy is noted to progress to left ventricular decompensation, dilatation and heart failure in approximately half of the rats (Bing et al. 1995; Norton et al. 1997; Tsotetsi et al. 2001). The second model of cardiac dilatation, a pharmacological model, was induced in 14 month old SHR (n=9) by chronic beta-adrenoreceptor activation [daily administration of the beta-adrenergic agonist isoproterenol (ISO) for a period of 4.5 months]. Chronic beta-adrenoreceptor activation in SHR, has been shown to enhance the progression from compensated left ventricular
hypertrophy to left ventricular dilatation (Badenhorst et al. 2003b; Gibbs et al. 2004). In this arm of the study, an SHR group receiving twice daily administration of the vehicle of isoproterenol (saline) for a period of 4.5 months (SHR-Control, n=9), served as the ‘non-failure’ group (see Figure 2.1 below).

The control group for this study comprised of 23 month old Wistar Kyoto (WKY) rats (n = 9; Kleinterfarm Madorin Ltd, Germany). These rats are the genetic controls for SHR (Tsotetsi et al. 2001). The WKY control group acted as such for both the natural progression model as well as the pharmacological model of the study (see Figure 2.1 below), as these rats are normotensive, and are not known to develop heart failure. Although the WKY control group of rats were older (23 months old) than the SHR-Control and SHR-ISO rats (both 18.5 months old), in normotensive rats in which body weight and heart weight are stable, age has been shown to have no impact on myocyte dimensions (Bai et al. 1990; Onodera et al. 1998; Tamura et al. 1998). We have previously reported no differences in body weight or left ventricular weight in 21-22 month old WKY compared to 12 month old WKY (Badenhorst et al. 2003b). Moreover, as it has previously been shown that chronic administration of a beta-adrenergic agonist to the WKY strain of rats does not induce cardiac dilatation (Badenhorst et al. 2003b; Gibbs et al. 2004) I did not include a WKY group receiving chronic beta-adrenergic agonist administration.

The rats were housed in pairs in cages in the CAS Unit of the University of the Witwatersrand and given food and water ad libitum until termination at 18.5 or 23 months of age.
Figure 2.1  Flow chart detailing the groups of rats

The control group acted as such for both models. In the natural progression model, rats found to have pathological features of cardiac failure (see 2.2.1 below) were assigned to the failure group, and rats without any features of cardiac failure were assigned to the non-failure group.

In the pharmacological model, the beta-adrenergic agonist, isoproterenol (or its vehicle, saline) was administered from 14 months of age until termination at 18.5 months of age.

ISO, isoproterenol; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.
2.1.1 Natural Progression Model

Eighteen 14 month old SHR (OLAC, UK) were housed in the CAS Unit of the University of the Witwatersrand. At 23 months of age the rats were terminated. At the time of termination, the rats were assessed for signs and symptoms of cardiac failure (see 2.2.1 below). Rats noted to have pathological features of cardiac failure were assigned to the failure group (SHR Failure, n=9), and rats without any features of cardiac failure were assigned to the non-failure group (SHR Non-Failure, n=9).

2.1.2 Pharmacological Model

Eighteen 14 month old SHR (OLAC, UK) were randomly assigned to two groups of nine rats each. One group (SHR-ISO) received a twice daily intraperitoneal injection of the beta-adrenergic agonist isoproterenol (ISO) (Imuprel, Adcock Ingram), at a concentration of 0.02 mg/kg/injection, in a volume of approximately 0.2 ml for 4.5 months. The other group (SHR-Control) received a twice daily injection of the vehicle of ISO (0.2 ml of 0.9% saline) for 4.5 months. The rats were terminated at 18.5 months of age.

2.2 SYSTOLIC BLOOD PRESSURE

Non-invasive systolic blood pressures (SBP) were assessed in all rats prior to the end of the study using a tail-cuff technique. In the pharmacological model, these measurements were obtained at least 24-hours after the last dose of ISO. To familiarise the rats to the procedure, rats were placed in restrainers, the tail pre-warmed and the tail cuff inflated every 15 minutes for an hour a day on five separate days prior to the measurements. To determine SBP, rat tails were pre-warmed until the tail artery pulse could be detected with a photoelectric diode coupled to a Model 29 pulse amplifier (IITC Inc.). A tail-cuff coupled to a pressure
transducer was placed on the rat tail proximal to the photoelectric diode and inflated until the tail pulse disappeared. The tail cuff pressure was then slowly released until the tail artery pulse returned. Systolic BP was taken as the cuff BP at which the tail artery pulse returned. Recordings of the tail cuff pressure and the pulse were made on a Beckman dynograph model R511A recorder, the recordings of which were calibrated both before and after each recording.

2.3 LEFT VENTRICULAR GEOMETRY

Rats in the pharmacological model (at 18.5 months of age), rats in the natural progression model (at 23 months of age) and the WKY control rats (at 23 months of age) were anaesthetised using an intraperitoneal injection of ketamine (75 mg/kg) and xylazine (15 mg/kg) (Bayer HealthCare, Animal Health). Once anaesthetised, a 14-gauge needle was placed in the trachea for positive pressure ventilation using room air through a constant–volume respirator (Harvard Apparatus, South Natuck, Massachusetts). The air in the ventilator was supplemented with oxygen to ensure adequate oxygen saturation.

The right carotid artery was catheterized using PP50 tubing. Placement of the carotid catheter allowed for the manual manipulation of ventricular filling as well as the measurement of systolic and diastolic arterial pressures and heart rate. A midline thoracotomy (sternotomy) was then performed.

Prior to performing a parietal pericardectomy, in the 23 month old rats (natural progression model), careful assessment was made for the presence of pleuropericardial effusions (the effusion was either in the pleura and/or the pericardium; see 2.2.1 below). Piezo-electric
ultra-sonic transducers, attached to a previously validated apparatus (Woodiwiss & Norton 1995; Trifunovic et al. 1995), were then placed across the short axis of the beating left ventricle (LV). These transducers emit ultra-sonic waves through one transducer (anteriorly, B in Figure 2.2) and receive the ultra-sonic waves through the other (posteriorly, C in Figure 2.2). The distance between the transducers was measured using a calibrated sonomicrometer (Triton Technology). The transducers were used to measure the external diameter of the left ventricle through the phases of the cardiac cycle over a range of left ventricular filling pressures (upper panel Figure 2.3).

The filling pressures were measured by means of the insertion of a 21-gauge needle through the apex of the heart (A in Figures 2.2 and 2.3). The 21-gauge needle was attached to a saline-filled PP25 polyethylene catheter which was coupled to a Gould P50 pressure transducer. The fluid filled catheter had amplitude-frequency responses which were uniform to 10Hz (Norton et al. 1997). Filling volumes were modified by the infusion of an iso-oncotic solution via the carotid catheter (Badenhorst et al. 2003b; Norton et al. 1997; Woodiwiss & Norton 1995; Tsotetsi et al. 2001). The frequent occurrence of extra systolic beats at filling pressures below 2 mm Hg prevented the collection of data at pressures below 2 mm Hg. The left ventricular end diastolic (LVED) diameters were therefore measured over a range of filling pressures between 2 mm Hg and 9 mm Hg.
Figure 2.2  Intraventricular pressure monitoring and piezo-electric ultrasonic transducers

Diagrammatic representation of the apical catheter (A) and the apparatus used for the placement of the piezo-electric ultrasonic transducers (B and C) across the short axis of the left ventricle. A, apical catheter attached to 21-gauge needle; B, anterior (transmitting) transducer; C, posterior (receiving) transducer.
Figure 2.3  Example of recordings of left ventricular external diameter measurements

Example of recordings of LV external diameter (LVExtD) obtained from the piezo-electric ultrasonic transducers (B and C in figure 2.2) and of LV diastolic pressure obtained from the apical catheter (A in figure 2.2) inserted into the left ventricle.

LVEDP, LV end diastolic pressure
All recordings were made on a Beckman Dynograph Recorder (type R511A). Left ventricular end diastolic radius (LVEDr) was calculated from the LVED external diameter measurements, using the following equation (Weber et al. 1988),

\[
\text{LVED radius} = \sqrt[3]{\frac{3}{V[\text{LVED external diameter} / 2]^3}} - \text{LV wall Volume} \left[\frac{3}{4} \pi \right]
\]

where,

\[
\text{LV wall volume} = 0.943 \times \text{LV wet weight}
\]

and where 0.943 represents the density of cardiac tissue (Tsotetsi et al. 2001; Woodiwiss and Norton 1995).

Left ventricular end diastolic wall thickness (LVEDh), was then determined using the equation,

\[
\text{LVEDh} = \frac{[(\text{LVED external diameter} - 2 \times \text{LVEDr})/2}{2}
\]

(Tsotetsi et al. 2001; Woodiwiss & Norton 1995); and from these measurements, LVED wall thickness to radius ratio (h/r) was calculated.

Using these values LVEDP-LVEDr and LVEDP-LVEDh/r relations were constructed in order to assess left ventricular geometry.

### 2.3.1 Identification of Failure and Non-failure Rats

In the natural progression model, rats were classified as in heart failure based upon the presence of pleuropericardial effusions and / or atrial thrombi. As stated above (see 2.2), at the time of thoracotomy and prior to pericardectomy careful assessment was made to identify
the presence or absence of pleuropericardial effusions. In addition, the presence or absence of atrial thrombi was identified at post-mortem (see 2.3 below).

Those animals that were found to have one or more of these pathological features of heart failure were assigned to the ‘SHR-Failure’ group (see Figure 2.1). Those rats that did not exhibit any pathological features of heart failure were assigned to the ‘SHR-Non-Failure’ group (see Figure 2.1). In order to confirm the presence of heart failure wet liver weights were determined in the SHR rats in the natural progression model and in the WKY control rats.

2.4 TISSUE SAMPLING

Once the collection of data to assess left ventricular geometry had been completed, a high dose (16mM) of potassium chloride (Hearse et al. 1975) was infused via the catheter into the carotid artery, hence arresting the heart in diastole. The heart was then removed, blotted dry and weighed. The right ventricular free wall was dissected away from the left ventricle and the left and right ventricles were weighed. During the dissection of the heart, the atria were removed and carefully inspected for the presence of thrombi (one of the features of heart failure).

Samples from the left ventricle were stored at −70 °C for later analysis. The samples were carefully labelled so that cardiac myocytes could be isolated from the same region of each heart for accurate comparisons.
2.5 MYOCYTE ISOLATION

Cardiac myocytes were isolated from the frozen tissue samples using a modification of a technique previously described (Diffee & Nagle 2003; Gerdes et al. 1998; Tamura et al. 1998). A sharp blade was used to carefully section off a 20 mg (wet weight, for light microscopy) or 100 mg (wet weight, for flow cytometry) piece of the LV posterior wall from the same region of each rat heart. Each piece of LV tissue was of full thickness, in that it extended from epicardium to endocardium.

Calcium-free physiological saline solution (PSS) was made for the cardiac myocyte isolation process. PSS consisted of NaCl 120 mmol, KCl 10 mmol, KH$_2$PO$_4$ 1.2 mmol, MgCl$_2$ 2.6 mmol, glucose 10 mmol, taurine 20 mmol, pyruvate 6.2 mmol and HEPES (4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid hemisodium salt) 4.8 mmol dissolved in 100 ml of distilled water (all chemicals obtained from Sigma Chemical Co., St. Louis, MO). 100ml of PSS was prepared for every 20mg of LV tissue. The PSS solution was titrated with 10 mM NaOH droplets until the pH of the solution was equal to a pH of 7.40 (physiological pH). The pH was measured using a pH meter (Beckman Φ32 pH meter, Beckman Instruments, Inc. USA). For every 20 mg of LV tissue, 50 ml of incubation solution and 50 ml of wash solution were prepared as described below.

The incubation solution consisted of 15 mg Collagenase Type 2 (Worthington Biochemical Corporation, Lakewood NJ, USA) at a concentration of 317 U/mg, 14mg of Hyaluronidase (Worthington Biochemical Corporation, Lakewood NJ, USA) at a concentration of 581 U/mg, 125 mg of bovine serum albumin (Fraction V, Sigma Chemical Co., St. Louis, MO) and 0.0227 ml of 110 mM CaCl$_2$ dissolved in 50 ml of PSS. The CaCl$_2$ (Sigma Chemical
Co., St. Louis, MO) was prepared by dissolving 1.617g of CaCl₂ into 100 ml of distilled water.

The wash solution consisted of 0.045 ml of 110 mM CaCl₂ and 250 mg of bovine serum albumin.

The sample of LV tissue was minced and then placed in a tissue culture flask containing 10 ml of the incubation solution. The tissue culture flask was then placed in a preheated (37 °C) oscillating water bath. The sample was oscillated in the water bath at a rate of 60 cycles per minute (slow shake), for a period of ten minutes. The incubation solution was then aspirated and a further 10 ml of fresh incubation solution was added to the flask with the tissue, followed by a second ten minute period of oscillations at the same rate. The incubation was then aspirated, and a 10 ml of fresh incubation solution was added. For the third period of oscillations the cycle rate was increased to 120 cycles per minute for a period of 15 minutes. Throughout the oscillation procedure the incubation solution containing the tissue was gassed with 95% O₂ – 5% CO₂.

The flask was then removed from the water bath, two thirds of the incubation solution aspirated and the remainder of the contents of the flask (incubation solution containing digested tissue and tissue precipitants) were flushed through a 250-μm nylon mesh into a 15-ml polypropylene test tube. The remaining tissue was then gently flushed through the nylon mesh using ~10 ml of the wash solution. The sample was then left to settle for 15 minutes after which the top two thirds of the supernatant was aspirated and ~10 ml of fresh wash solution was added to the test tube. Following a second settling step of 15 minutes the supernatant was aspirated without disturbing the pellet of cells. The cells were then diluted in
PSS containing 0.01% bromophenyl blue (The Coleman and Bell Co., USA) which stains proteins, hence allowing for the easy identification of striations (sarcomere bands) within the cardiac myocytes (Figure 2.4). The diluted cell sample was then aliquoted into tissue culture dishes for analysis under light microscopy. Approximately 55-75% of the cells in the suspension were rod-shaped cardiac myocytes (Figure 2.4).

2.6 LIGHT MICROSCOPY

LV tissue from all rats in both models (natural progression and pharmacological) plus LV tissue from the WKY control group of the study, was assessed under light microscopy. Using an inverted light microscope (A, Figure 2.5), images seen under the microscope were relayed to a computer program using a digital camera (B, Figure 2.5) (Nikon Digital Sight DS-U1 & DS-5M, Nikon Corporation, Japan). The cells were viewed at 400x magnification and cardiac myocytes were selected based on the ability to see and count most of the sarcomere bands from one end of the cardiac myocyte to the other (Figure 2.6). Between 25 and 30 cardiac myocytes were selected from each LV tissue sample. Using the program, Act2U (Ver. 1.70 Nikon Corporation, Japan), the dimensions of each cardiac myocyte were measured. The software was calibrated using a 0.01 x 100 = 1mm graticule (Graticules Ltd, Tonbridge, Kent, England). All images were saved on hard drive before being assessed. Saving of the images ensured that the cardiac myocyte images were not moving during the measurements and that the measurements could be reassessed at anytime. The dimensions measured were the length (A, Figure 2.6), width (B, Figure 2.6) and sarcomere length (distance between Z-bands) (C, Figure 2.6) of each cardiac myocyte. The length to width ratio of each cardiac myocyte was calculated. The 30-35 cardiac myocyte dimensions obtained were then averaged for each sample of LV tissue. From these group means were then calculated.
**Figure 2.4  Examples of isolated cardiac myocytes**

An example of ~70% rod-shaped isolated cardiac myocytes (A) surrounded by cell debris, non-viable cardiac myocytes or cells which are not cardiac myocytes (B) (upper panel) and a rod-shaped isolated cardiac myocyte (lower panel)
Figure 2.5   Photograph of digital camera and microscope

Photograph showing inverted microscope (A) to which digital camera (B) is attached. The
digital camera is coupled to a computer running Act2U software and an image of a cardiac
myocyte is displayed on the computer screen (C).
Figure 2.6  An example of striations of an isolated cardiac myocyte

Photograph of a cardiac myocyte showing striations and the measurement of length (A), width (B) and sarcomere length (C).
2.7 FLOW CYTOMETRY

As using light microscopy, relatively few cardiac myocytes can be measured in comparison to the total number of cardiac myocytes, I wished to also determine cardiac myocyte dimensions using a procedure which allows for the measurement of vast numbers of cells (~30 000 cells) in a short period of time. In order to do this I devised a method to measure cardiac myocyte dimensions using flow cytometry based upon previously described methods (Diez & Simm 1998; Nash et al. 1979). For the assessment of cardiac myocyte dimensions using flow cytometry, cardiac myocytes were isolated from 100mg of LV tissue from each of the rats (those in the natural progression model; those in the pharmacological model and the WKY control rats) using the same procedure as described above (see 2.4). However, after cardiac myocyte isolation, the cells were not stained with bromophenol blue; they were suspended in 1ml of PSS and placed in 5ml Polystyrene round bottom tubes (Falcon, Becton-Dickinson, USA) rather than in cell culture dishes.

Cardiac myocyte morphometry was assessed using a Becton-Dickinson flow cytometer (FACSCalibur®, Franklin Lakes, NJ) (see Figure 2.7). Fluorescence in the FL1 channel was quantified at a single cell level and data were analysed using Cellquest® version 3.3 (Becton Dickinson software). The flow cytometer was preset to measure a maximum of 30 000 cells per sample. The cardiac myocytes were not stained as they autofluoresce, hence allowing for their detection and the assessment of their forward and side scatter. Side scatter gives an indication of cell granularity (number of intracellular organelles and/or proteins) and forward scatter a measure of relative cell size (based upon the shape of the cell and the degree of folding of the cell membrane). A dot plot of side versus forward scatter (Figure 2.8) was then drawn. The side versus forward scatter dot plot was then gated (A, Figure 2.8) to exclude...
debris and cells which are not cardiac myocytes (cells with low granularity) (Strijdom H et al. 2004).

The measurement of cell length by the flow cytometer was achieved by the determination of the time of flight (FL1-W). The cardiac myocytes are passed through the flow chamber through which the excitation light source is shone at 90°. The longer the cardiac myocytes are, the greater is the period of time that the cardiac myocytes are in the path of the laser beam (called the time of flight) (Figure 2.9). Hence longer cardiac myocytes have a greater time of flight or FL1-W (Figure 2.10). In order for this measurement of cardiac myocyte length to be calibrated rod-shaped beads would be required. As at present only cylindrical calibration beads are available, I have indicated these cardiac myocyte length measurements as unitless. FL1-W measurements of ~15 000 to 20 000 cardiac myocytes were obtained for each LV specimen. From these measurements group means were calculated.

2.8 STATISTICAL ANALYSES

All data were compared between the five groups in the two models of dilatation; i.e. the SHR-Failure and SHR-Non-Failure for the natural progression model; the SHR-Control and SHR-ISO treated groups for the pharmacological model and the WKY control group. An analysis of variance (ANOVA) was performed followed by a Student-Newman-Keuls post-hoc test to assess for differences between the groups. The relations between cardiac myocyte length and LVED radius; light microscopy cardiac myocyte length and flow cytometry cardiac myocyte length; and cardiac myocyte length and LV weight normalised to 100g body weight were determined using linear correlation analysis (Pearson’s). All data are represented as mean ± SEM (standard error of the mean). The significance level was set at p<0.05.
Figure 2.7  Flow cytometer

A photograph of the Becton-Dickinson flow cytometer (FACSCalibur®).
Figure 2.8   Example of flow cytometer dot plot

Dot plot of side scatter height (SSC-H) and forward scatter height (FSC-H) of cardiac myocytes. The dot plot was gated (A) from a SSC-H of above 200 in order to exclude debris and cells which are not cardiac myocytes [cells with low granularity (SSC-H)].
Figure 2.9  Diagrammatic representation of a cardiac myocyte in the path of the flow cytometer laser beam

Diagrammatic representation of a cardiac myocyte (A) in the path of the laser beam (B). As indicated in the graph, the time of flight counts (y-axis) increase as the cardiac myocyte passes from ~⅓ (1) to the whole (3) of the cell being in the path of the laser beam.
Figure 2.10  Plot of cardiac myocyte counts versus time of flight

Plot of counts versus time of flight (FL1-W) for cardiac myocytes from a normotensive WKY rat (purple), a SHR-NF rat (light pink) and a SHR-F rat (dark pink).
CHAPTER 3
3.0 RESULTS

3.1 LEFT VENTRICULAR GEOMETRY

3.1.1 Natural Progression Model

3.1.1.1 Body and Tissue Weights and Blood Pressures

Both heart weight and LV weight were increased in the SHR-Failure and SHR-Non-Failure groups when compared to the WKY control group (Table 3.1). However, the body weights of the WKY control group were greater than those of both the SHR-Failure and the SHR-Non-Failure groups. Nevertheless, LV weight standardised to 100g body weight remained increased in both the SHR-Failure and the SHR-Non-Failure groups compared to the WKY control group (Table 3.1). Consistent with the increased heart and LV weights, both SHR groups had increased SBP compared to the WKY group (Table 3.1).

Despite similar body weights; heart weight, LV weight and LV weight normalised to 100g body weight ratio were greater in the SHR-Failure group compared to the SHR-Non-Failure group. Consistent with the presence of heart failure, both RV weight and wet liver weight were increased in the SHR-Failure group compared to the SHR-Non-Failure group and the WKY control group (Table 3.1).

3.1.1.2 LV Dimensions

The LV end diastolic radius of the SHR-Failure group was significantly greater than that of the SHR-Non-Failure group throughout the measured LV end diastolic pressure range of 2 – 9 mm Hg (Figure 3.1, upper panel), but was only greater than that of the WKY control group at an LV end diastolic pressure of 9 mm Hg. Bearing in mind the increased body weight in the WKY control group, the LV end diastolic radius was normalised to 100g body weight. Throughout the measured LV end diastolic pressure range of 2-9 mm Hg, the LV end diastolic radius normalised to 100g body weight was greater in the SHR-Failure group.
Table 3.1  Body and tissue weights in the natural progression model and in the pharmacological model

<table>
<thead>
<tr>
<th></th>
<th>Normotensive control</th>
<th>Natural progression model</th>
<th>Pharmacological model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WKY</td>
<td>SHR-Non-Failure</td>
<td>SHR-Failure</td>
</tr>
<tr>
<td>Number</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>418±6</td>
<td>344±9**</td>
<td>336±8***</td>
</tr>
<tr>
<td>Heart weight (g)</td>
<td>1.35±0.03</td>
<td>1.75±0.03***</td>
<td>1.96±0.03***†‡</td>
</tr>
<tr>
<td>LV weight (g)</td>
<td>0.99±0.02</td>
<td>1.32±0.02***</td>
<td>1.50±0.02***†‡</td>
</tr>
<tr>
<td>LV weight / 100g body weight</td>
<td>0.238±0.006</td>
<td>0.383±0.009***</td>
<td>0.446±0.011***†‡</td>
</tr>
<tr>
<td>RV weight (g)</td>
<td>0.36±0.01</td>
<td>0.41±0.01</td>
<td>0.48±0.01***††‡‡</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>13.10±0.38</td>
<td>13.48±0.48</td>
<td>15.41±0.75*†</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>128±8</td>
<td>188±7***</td>
<td>190±8***</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. The WKY normotensive group was the control group for both models.

*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; †p<0.05, ††p<0.001 compared to the SHR-Non-Failure group; #p<0.05, ##p<0.01, ###p<0.001 compared to the SHR-Control group; ‡p<0.05, ‡‡p<0.01 versus SHR-Control group; §p<0.05, §§p<0.01 versus SHR-Non-Failure group.
Figure 3.1  Left ventricular end diastolic radius – pressure relations in the natural progression model

Left ventricular (LV) end diastolic radius – pressure relations (upper panel) and these relations after normalising LV radius to 100g body weight (BW) (lower panel) for the three groups in the natural progression model.

*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; †p<0.05, ††p<0.01, †††p<0.001 compared to the SHR-Non-Failure group.
compared to those of the SHR-Non-Failure group and the WKY control group (Figure 3.1, lower panel). The increased LV end diastolic radius normalised to 100g body weight in the SHR-Failure group is indicative of the presence of LV dilatation.

Throughout the measured LV end diastolic pressure range of 2-9 mm Hg, the LV end diastolic wall thickness to radius ratio was higher in the SHR-Non-Failure group compared to that of the WKY control group, consistent with compensatory concentric geometry (Figure 3.2). Moreover the LV end diastolic wall thickness to radius ratio in the SHR-Failure group was decreased compared to that of the SHR-Non-Failure group and was no different to that of the WKY controls (Figure 3.2). The decreased LV end diastolic wall thickness to radius ratio in the SHR-Failure group is consistent with the presence of LV decompensation and dilatation.

### 3.1.2 Pharmacological Model

#### 3.1.2.1 Body and Tissue Weights

Body weight was lower but heart weight and LV weight were greater in the SHR-Control and SHR-ISO groups when compared to the WKY control group (Table 3.1). In addition, the SHR-ISO group had significantly greater heart weight and LV weight than the SHR-Control group (Table 3.1). Furthermore, the LV weight normalised to 100g body weight of the SHR-Control and SHR-ISO groups was greater than that of the WKY control group. Moreover, the LV weight normalised to 100g body weight of the SHR-ISO group was greater than that of the SHR-Control group (Table 3.1). In the SHR-ISO group, RV weight was increased compared to both the SHR-Control and the WKY groups, consistent with the presence of LV failure in the SHR-ISO group.
Figure 3.2 Left ventricular end diastolic wall thickness to radius ratio – pressure relations in the natural progression model

Left ventricular (LV) end diastolic wall thickness to radius ratio – pressure relations for the three groups in the natural progression model.

*p<0.05, **p<0.01 compared to the WKY control group; †p<0.05, ††p<0.01 compared to the SHR-Non-Failure group.
3.1.2.2 LV Dimensions

The LV end diastolic radius of the SHR-ISO group were increased compared to those of both the WKY control and the SHR-Control groups throughout the measured LV end diastolic pressure range of 2 – 9 mm Hg (Figure 3.3, upper panel), indicative of the presence of LV dilatation in the SHR-ISO group. Similarly, the LV end diastolic radius normalised to 100g body weight was increased in the SHR-ISO group compared to both the SHR-Control and the WKY control groups throughout the measured LV end diastolic pressure range of 2-9 mm Hg (Figure 3.3, lower panel). No differences were noted between the SHR-Control and WKY control groups.

Indicative of the presence of compensatory concentric geometry, the LV end diastolic wall thickness to radius ratio at LV end diastolic pressures of 2-6 mm Hg was increased in the SHR-Control group (Figure 3.4). In comparison, at LV end diastolic pressures of 2-6 mm Hg, the LV end diastolic wall thickness to radius ratio in the SHR-ISO group was lower than that of the SHR-Control group and was no different from that of the WKY control group (Figure 3.4). The decreased LV end diastolic wall thickness to radius ratio in the SHR-ISO group is indicative of LV decompensation and dilatation.

3.2 MYOCYTE DIMENSIONS

3.2.1 Natural Progression Model

3.2.1.1 Light microscopy

There was a significant increase in the length of the cardiac myocytes of the hypertensive groups (SHR-Failure and SHR-Non-Failure groups) when compared to the normotensive (WKY) group (Figure 3.5, upper panel). Importantly, there was no difference in the cardiac myocyte lengths between the two hypertensive groups. Hence, despite the presence of LV
Figure 3.3  Left ventricular end diastolic radius – pressure relations in the pharmacological model

Left ventricular (LV) end diastolic radius – pressure relations (upper panel) and these relations after normalising LV radius to 100g body weight (BW) (lower panel) for the three groups in the pharmacological model.

*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; ##p<0.01, ###p<0.001 compared to the SHR-Control group.
Left ventricular (LV) end diastolic wall thickness to radius ratio – pressure relations for the three groups in the pharmacological model.

*p<0.05, **p<0.01 compared to the WKY control group; #p<0.05, ##p<0.01 compared to the SHR-Control group.

Figure 3.4  Left ventricular end diastolic wall thickness to radius ratio – pressure relations in the pharmacological model
dilatation, the SHR-Failure rats had cardiac myocytes of similar length to those of the SHR-Non-Failure rats (absence of LV dilatation) (Figure 3.5, upper panel). Consistent with an increased cardiac myocyte length in the hypertensive groups, a right shift in the frequency distribution of cardiac myocyte lengths was noted in the SHR-Non-Failure and SHR-Failure groups in comparison to the WKY control group (Figure 3.5, lower panel).

No differences were noted for either cardiac myocyte width (Figure 3.6, upper panel) or the cardiac myocyte length to width ratio (Figure 3.6, lower panel) between the SHR-Failure, SHR-Non-Failure and WKY groups. In addition no differences in sarcomere length (μm) (WKY: 1.87±0.04; SHR-Non-Failure: 1.99±0.04; SHR-Failure: 2.00±0.04) or sarcomere number (WKY: 45±2; SHR-Non-Failure: 46±2; SHR-Failure: 46±2) were noted between the three groups.

3.2.1.2 Flow Cytometry
The data collected from the same rat hearts using flow cytometry indicated a similar pattern as that shown with light microscopy. The length (FL1W) of the WKY cardiac myocytes was significantly decreased as compared to that of the two hypertensive groups, SHR-Failure and SHR-Non-Failure (Figure 3.7). Moreover, no differences in cardiac myocyte length (FL1W) were noted between the SHR-Failure and the SHR-Non-Failure groups (Figure 3.7), indicating that despite differences in LV dimensions (Figures 3.1 and 3.2), no differences in cardiac myocyte length (FL1W) were noted.
Figure 3.5  Cardiac myocyte lengths and frequency distribution of cardiac myocyte lengths in the natural progression model

Cardiac myocyte lengths (upper panel) and frequency distribution of cardiac myocyte lengths (lower panel) as assessed by light microscopy in the three groups of the natural progression model.

***p<0.001 compared to the WKY control group.
Figure 3.6  Cardiac myocyte widths and length to width ratios in the natural progression model

Cardiac myocyte widths (upper panel) and length to width ratios (lower panel) as assessed by light microscopy in the three groups of the natural progression model.

No significant differences were noted between the three groups.
**Figure 3.7** Cardiac myocyte lengths as assessed by flow cytometry in the natural progression model

Cardiac myocyte lengths as assessed by flow cytometry (FL1W) in the three groups of the natural progression model.

*p<0.05, **p<0.01 compared to the WKY control group.
3.2.2 Pharmacological model

3.2.2.1 Light microscopy

There was a significant increase in the length of the cardiac myocytes of the SHR-Control and SHR-ISO groups when compared to those of the normotensive WKY control group (Figure 3.8, upper panel). Importantly, there was no difference in the length of the cardiac myocytes of the SHR-ISO group compared to those of the SHR-Control groups (Figure 3.8, upper panel). Hence, despite the presence of cardiac dilatation in the SHR-ISO group, but not in the SHR-Control group, the cardiac myocyte length was no different between these two groups. Consistent with an increased cardiac myocyte length in the hypertensive groups, a right shift in the frequency distribution of cardiac myocyte lengths was noted in the SHR-Control and SHR-ISO groups in comparison to the WKY control group (Figure 3.8, lower panel).

The cardiac myocyte widths of the SHR-ISO and SHR-Control groups were no different from those of the WKY control group (Figure 3.9, upper panel). In addition, no differences in the cell length to width ratios were noted between the three groups (Figure 3.9, lower panel). A modest increase (p<0.05) in sarcomere length (μm) was noted in SHR-Control (2.10±0.04) and SHR-ISO (2.13±0.04) in comparison to WKY (1.87±0.04). However, no differences in sarcomere number (WKY: 45±2; SHR-Control: 40±2; SHR-ISO: 40±2) were noted between the three groups.
Figure 3.8    Cardiac myocyte lengths and frequency distribution of cardiac myocyte lengths in the pharmacological model

Cardiac myocyte lengths (upper panel) and frequency distribution of cardiac myocyte lengths (lower panel) as assessed by light microscopy in the three groups of the pharmacological model.

*p<0.05 compared to the WKY control group.
Figure 3.9  Cardiac myocyte widths and length to width ratios in the pharmacological model

Cardiac myocyte widths (upper panel) and length to width ratios (lower panel) as assessed by light microscopy in the three groups of the pharmacological model.

No significant differences were noted between the three groups.
3.2.2.2 Flow Cytometry

The data collected from the same rat hearts using flow cytometry indicated a similar pattern as that shown with light microscopy. The length (FL1W) of the WKY cardiac myocytes was significantly shorter as compared to that of the SHR-Control and SHR-ISO groups (Figure 3.10). Importantly, despite differences in LV dimensions (Figures 3.3 and 3.4) no difference in cardiac myocyte length (FL1W) was evident between the SHR-ISO and SHR-Control groups (Figure 3.10).

3.3 CORRELATIONS

3.3.1 Left ventricular end diastolic radius and cardiac myocyte length

Linear correlation analyses between LV end diastolic radius and cardiac myocyte length (Figure 3.11, light microscopy, upper panel and flow cytometry, lower panel) were performed using data from all groups (SHR-Non-Failure, SHR-Failure, WKY, SHR-Control, SHR-ISO). Despite a range of light microscopy mean myocyte lengths (~70-110 μm) and mean LV end diastolic radii (~0.1-0.6 cm), no correlation was observed (Figure 3.11, upper panel). Furthermore, no correlation was observed between flow cytometry myocyte lengths and LV end diastolic radii (Figure 3.11, lower panel).

3.3.2 Cardiac myocyte lengths obtained using light microscopy versus flow cytometry

The two techniques used to measure cardiac myocyte length were linearly correlated (Figure 3.12). The cardiac myocytes from the WKY control rats were the smallest (in the left of Figure 3.12) and no differences between the four SHR groups were evident (there is considerable overlap of the data obtained in these four groups, Figure 3.12). Using these two techniques the same differences were shown between the groups (compare figures 3.5 and 3.7; compare Figures 3.8 and 3.10). Hence, although absolute measurements of cell length
Cardiac myocyte lengths as assessed by flow cytometry (FL1W) in the three groups of the pharmacological model.

*p<0.05 compared to the WKY control group.
Figure 3.11  Linear correlation analyses between left ventricular end diastolic radius and cardiac myocyte length

Linear correlation analyses between left ventricular (LV) end diastolic radius and cardiac myocyte length as assessed by light microscopy (upper panel) and flow cytometry (lower panel) using data obtained in all groups.
Figure 3.12  Linear correlation analysis between cardiac myocyte length measured using light microscopy and flow cytometry

Linear correlation analysis between cardiac myocyte length measured using light microscopy (y-axis) and cardiac myocyte length assessed using flow cytometry (FL1W, x-axis) using data obtained in all groups.
cannot be obtained using flow cytometry, due to the inability to calibrate at present, differences in cardiac myocyte length between groups can be assessed using this technique.

### 3.3.3 Left ventricular weight (mg/100g body weight) versus cardiac myocyte length

A strong association was noted between LV weight normalised to 100g body weight and cardiac myocyte length measured using either light microscopy (Figure 3.13, upper panel) or flow cytometry (Figure 3.13, lower panel).
Figure 3.13  Linear correlation analyses between left ventricular weight normalised to 100g body weight and cardiac myocyte length as assessed by light microscopy and flow cytometry

Linear correlation analyses between left ventricular (LV) weight normalised to 100g body weight and cardiac myocyte length as assessed by light microscopy (upper panel) and flow cytometry (lower panel) using data obtained in all groups.
CHAPTER 4
The main findings of the present study are as follows: The length of cardiac myocytes isolated from rats with LV dilatation (SHR-Failure and SHR-ISO) was no different from the length of cardiac myocytes isolated from rats without LV dilatation (SHR-Non-Failure and SHR-Control). The two models of LV dilatation used [natural progression model (SHR-Failure) and pharmacological model (SHR-ISO)] revealed the same outcome that LV dilatation (increased LV end diastolic radius and decreased LV wall thickness to radius ratio) is not associated with an increase in cardiac myocyte length. Furthermore, the data were confirmed using two methods (light microscopy and flow cytometry) to determine cardiac myocyte length. However, the hypertensive rats (SHR-Non-Failure; SHR-Failure; SHR-Control; SHR-ISO) did have an increased cardiac myocyte length compared to that of normotensive rats (WKY control).

The present study clarifies that although alterations in cardiac myocyte dimensions accompany hypertension-induced cardiac hypertrophy (Bishop et al. 1979; McCrossan et al. 2004; Olivetti et al. 1994; Zierhut et al. 1991), further increases in cardiac myocyte length are not a mechanism of the development of cardiac dilatation and heart failure. The present study is the first study to assess cardiac myocyte dimensions in age-matched animals with cardiac dilatation and to accurately determine LV dilatation using load independent measurements. Our data showing that LV dilatation is not associated with increases in cardiac myocyte length are in contrast to a number of studies mostly from the same group (Chen et al., 2010; Gerdes et al. 1996; Onodera et al. 1998; Schultz et al., 2007; Tamura et al. 1998, 1999 and 2000) that report increases in cardiac myocyte length in rats in heart failure.
As a model of heart failure, Gerdes and his colleagues (Gerdes et al. 1996; Onodera et al. 1998; Tamura et al. 1998, 1999 and 2000) have used rats that are genetically predisposed to the development of heart failure with increasing age (spontaneously hypertensive heart failure, SHHF). Consequently, in all of their studies the rats with heart failure were 3 to 16 months older than those rats not in heart failure (Gerdes et al. 1996: 24 versus 12 months; Onodera et al. 1998: 12 versus 9 months; Tamura et al. 1998, 1999 and 2000: 18 versus 2, 16 versus 6 and 22 versus 18 months respectively). As cardiac myocyte length is strongly correlated with age in SHHF rats (Tamura et al. 1998) and with LV weight (Campbell et al. 1991; Capasso et al. 1992; current study), and LV weight increases with age in hypertensive rats (Gerdes et al. 1996), the increased cardiac myocyte length observed in the SHHF rats with heart failure may be attributed to the increased age and hence LV weight of these rats rather than the presence of increased LV dimensions and heart failure. Moreover, in a study to assess reverse remodelling, an angiotensin II type 1 receptor blocker resulted in a decrease in myocyte length associated with a decrease in heart weight but no change in LV internal dimensions in age-matched SHHF rats (Tamura et al. 2000). In addition, although differences in cardiac myocyte length and heart weight between the angiotensin II type 1 receptor blocker treatment group and the hydralazine treatment group were noted, no differences in LV internal dimensions between these two groups were evident (Tamura et al. 2000).

Few previous studies have simultaneously measured cardiac myocyte length and LV dimensions. Most studies reporting increases in cardiac myocyte length in rats with heart failure compared to rats without heart failure have failed to measure LV dimensions (Gerdes et al. 1996; Onodera et al. 1998; Tamura et al. 1998 and 1999). Hence, whether increases in cardiac myocyte length accompany LV dilatation is not evident from these studies. Moreover, the few studies which have assessed LV dimensions have used in vivo echocardiography,
which is dependent on loading conditions and heart rate. Hence the increases in LV dimensions reported previously (Tamura et al. 2000) may be as a consequence of increases in loading conditions rather than the presence of LV remodelling and dilatation. Indeed in SHHF rats increases in LV internal dimensions are accompanied by increases in LV systolic wall stress (afterload) (Tamura et al. 2000) and decreases in LV internal dimensions occurred when LV systolic wall stress was reduced (Tamura et al. 2000). Similarly, in both aortic banded guinea pigs (Wang et al. 1999) and supraventricular tachycardia-induced cardiomyopathy in pigs (Spinale et al. 1996), increases in LV internal dimensions were measured in the presence of increases in afterload (systolic wall stress) and preload (LV end diastolic pressure). Furthermore, the reductions in LV end diastolic diameter reported following LV assist device support are likely to be due to the decreases in pulmonary capillary wedge pressure (preload) as a consequence of LV assist device support (Zafeiridis et al. 1998). Although, one previous study did not use echocardiography, they measured LV dimensions of cardiac rings following perfusion fixation (Kajstura et al. 1995), in which the perfusion pressure was maintained equal to the LV end diastolic pressure measured in vivo. As the LV filling pressure was increased in the dogs with pacing-induced heart failure, the increased LV dimensions reported are likely to be attributed to the increased preload (Kajstura et al. 1995). Moreover, reductions in cardiac myocyte length have been reported when cardiac preload and/or afterload are decreased (Campbell et al. 1991; Cooper et al. 1982 and 1984; Thompson et al. 1984). In contrast in the present study, LV dilatation was defined as the presence of an increased LV end diastolic radius and a decreased LV end diastolic wall thickness to radius ratio determined over a range of controlled LV filling volumes in vivo. Hence, the increases in LV dimensions in the current study are an accurate indication of the presence of LV dilatation independent of loading conditions.
A further explanation for the discrepancy between our data and that of others may be the difference in the strain of rats used. In the studies by Gerdes and colleagues (Gerdes et al. 1996; Onodera et al. 1998; Tamura et al. 1998, 1999 and 2000) the SHHF model has been used predominantly. However, the genetic background of the SHHF rat strain differs from that of the SHR and WKY rat strains (McCune et al. 1990; 1995a and 1995b). Moreover, the SHHF rat strain is reported to have longer cardiac myocytes than normal adult rats (Gerdes et al. 1996), a difference that was noted long before the development of the clinical signs and decreased hemodynamic function associated with heart failure (Onodera et al. 1998). Typically SHHF rats not in heart failure have cardiac myocyte lengths of ~140 to 150 μm (Capasso et al. 1992; Tamura et al. 1999), whereas mean cardiac myocyte lengths of 109 to 145 μm and 94 to 110 μm have been reported in the Sprague-Dawley (Bai et al. 1990; Korecky & Rakusan 1978; Nash et al. 1979) and Fischer (Bishop & Drummond 1979) strains of rats respectively. Similar to the results of the present study, previous studies reported longer cardiac myocytes in SHR compared to WKY rats (Aiello et al. 2004; Bishop et al. 1979; Brooksby et al. 1992; McCrossan et al. 2004). In these previous studies cardiac myocyte lengths ranged from 93 to 140 μm in WKY and from 105 to 150 μm in SHR (Aiello et al. 2004; Bishop et al. 1979; Brooksby et al. 1992; McCrossan et al. 2004) and in the present study we report mean cardiac myocyte lengths of 76 μm in WKY rats and 86 to 96 μm in SHR. Hence, even within rat strain there is a wide range of cardiac myocyte lengths. Differences within strain may be related to differences in the origin of the rats, as those SHR and WKY obtained from the same source have similar cardiac myocyte lengths (Bishop et al. 1979: WKY=93 μm and SHR=105 μm; Brooksby et al. 1992: WKY=95 μm and SHR=115 μm; both from Charles River Breeding Laboratory); whereas WKY and SHR from a different source (bred in the researchers own facility as opposed to from Charles River Breeding Laboratory) have different cardiac myocyte lengths (WKY=136 μm and SHR=147 μm;
Aiello et al. 2004). Similarly, Sprague-Dawley rats obtained from different sources (Bio-Breeding Laboratories: Korecky & Rakusan 1978 versus Holtman Company: Bai et al. 1990) have different cardiac myocyte lengths (120 μm: Korecky & Rakusan 1978; 145 μm: Bai et al. 1990). In this regard the SHR used in the present study were bred in the Central Animal Services at the University of the Witwatersrand. The original breeding pairs were obtained over 20 years ago from OLAC, UK. It has also been reported that differences in cardiac myocyte size can be present in different shipments of a given strain of rats (Campbell et al. 1991). In addition, cardiac myocyte lengths vary across species. Mean cardiac myocyte lengths of 122 to 137 μm have been reported in normal adult hamsters (Sorenson et al. 1985) and in normal adult guinea pigs mean cardiac myocyte length is 168 μm (Wang et al. 1999).

It may also be argued that the method of cell isolation may impact upon cardiac myocyte dimensions. Fixation after isolation does not appear to impact upon cardiac myocyte length (freshly isolated: 109 μm; fixed: 109 μm; Nash et al. 1979); however, plated cardiac myocytes are longer (147 μm, Fraticelli et al. 1989) than those freshly isolated (110 μm, Sorenson et al. 1985) from the same strain of rat of the same age (Wistar). Nevertheless, Diffee and Nagle (2003), who used a similar method of isolation as in the present study (ie. from frozen tissue) report cardiac myocyte lengths of 123 μm which are no different from those of cardiac myocytes freshly isolated (120 μm, Korecky and Rakusan 1978) from the same strain (Sprague Dawley) of rats of the same age. Hence it is unlikely that the method of cell isolation used in the present study had an impact on the cardiac myocyte lengths recorded. Furthermore, the slack (relaxed) sarcomere lengths of 1.87 μm (WKY) and 1.99 to 2.13 μm (SHR) recorded in the present study are similar to those recorded in previous studies 1.60 μm (Fischer: Bishop and Drummond, 1979), 1.62 μm (Wistar, WKY and SHR: Bishop et al. 1979), 1.80 μm (Sprague-Dawley: Korecky & Rakusan 1978) 1.81 μm (WKY) and 1.85

Lastly, the discrepancy between the results of our study and that of previous studies may be related to differences in the models of LV dilatation and heart failure. Besides the SHHF rat model (Gerdes et al. 1996; Onodera et al. 1998; Tamura et al. 1998, 1999 and 2000), cardiac myocyte lengths have been assessed in two other models of heart failure, namely supraventricular tachycardia-induced cardiomyopathy in pigs (Spinale et al. 1996) and dogs (Kajstura et al. 1995), and constriction of the descending thoracic aorta in guinea pigs (Wang et al. 1999). Consistent with the SHHF model, in these two models increases in cardiac myocyte length have been reported in the group with increased LV end diastolic dimensions (Kajstura et al. 1995; Spinale et al. 1996; Wang et al. 1999). However, as cardiac dilatation has been attributed to alterations in both cardiac myocyte dimensions and myocardial fibrosis in dilated cardiomyopathy in humans (Beltrami et al. 1995), and changes in myocyte volume are reported to correlate with alterations in heart mass unless there is extensive fibrosis (Gerdes, 2002), it is important to assess the relative contribution of each of these factors to LV remodelling. In this regard, Campbell et al. (1991) attribute increases in heart weight despite no change in cardiac myocyte size to increases in myocardial fibrosis. Importantly, in the SHHF model only modest increases in myocardial collagen content (an increase from 1.9 to 2.5%; Onodera et al. 1998; Tamura et al. 1998) have been noted. Similarly, there is a lack of myocardial fibrosis in the aortic banding model (Wang et al. 1999), and in tachycardia-induced cardiomyopathy myocardial collagen concentrations are either decreased (Spinale et al. 1996) or modestly increased (from 0.5 to 6%, Kajstura et al. 1995). In contrast, in both the natural progression (SHR-Failure) and the pharmacological (SHR-ISO) model used in the
present study, we have previously shown that alterations in the characteristics of myocardial collagen play a major role in determining LV remodelling and dilatation (Anamourlis et al. 2006; Badenhorst et al. 2003a and 2003b; Tsetetsi et al. 2001; Veliotes et al. 2005; Woodiwiss et al. 2001), data which is supported by studies showing increased fibrosis in SHR in heart failure (Boluyt et al. 1995; Conrad et al. 1995; Engelmann et al. 1987). Hence it is not surprising that we found no contribution of cardiac myocyte length to LV dilatation; whereas in models in which fibrosis plays little role (Kajstura et al. 1995; Onodera et al. 1998; Spinale et al. 1996; Tamura et al. 1998; Wang et al. 1999), alterations in cardiac myocyte length were observed.

In agreement with previous studies conducted in SHR (Boluyt et al. 1995; Conrad et al. 1995; Engelmann et al. 1987), no changes in cardiac myocyte dimensions were noted in SHR with LV dilatation in the present study. In this regard, Engelmann et al. (1987) report no change in cardiac myocyte cross-sectional area but substantial increases in myocardial fibrosis in SHR with decreased LV wall thickness. Similarly, Boluyt et al. (1995) and Conrad et al. (1995) report decreases in cardiac myocyte fractional area and increased myocardial fibrosis in SHR in heart failure.

Furthermore, in support of the lack of association between cardiac myocyte length and LV dimensions observed in the present study; Schultz et al. (2007) showed that 16 months of exercise in SHHF rats resulted in a 21% increase in LV diastolic diameter, but no change in myocyte length. The deleterious effects of exercise on cardiac remodelling (enhanced LV dilatation) were however associated with a profound increase in cardiac fibrosis (~140%). Similarly, the prevention of increases in cardiac chamber diameter, by thyroid administration in cardiomyopathic hamsters, was associated with no change in cardiac myocyte length.
(Kuzman et al., 2007). In a study assessing the impact of TNF-α overexpression on cardiac remodelling; although cardiac myocyte length was increased in both male and female rats, increases in LV diastolic diameter were only observed in the male rats (Janczewski et al. 2003). Moreover, Tamura et al., (2000) reported decreases in cardiac myocyte length subsequent to angiotensin II receptor blockade; however no changes in cardiac dimensions were noted. Lastly, increases rather than decreases in cardiac myocyte length were reported in a recent study in which intramyocardial delivery of mesenchymal stem cells resulted in the prevention of cardiac dilatation following myocardial infarction in mice (Li et al., 2010).

Although a limitation of the present study may be the use of cardiac myocytes isolated from frozen tissue, this is unlikely. As previously discussed the lengths of cardiac myocytes isolated from frozen tissue (123 μm, Diffee & Nagle, 2003) are no different from those of freshly isolated cardiac myocytes (120 μm, Korecky & Rakusan 1978). In addition, the method used to isolate cardiac myocytes is more likely to impact on absolute length measurements than on comparisons between groups. Hence, the lack of difference in cardiac myocyte lengths between rats with LV dilatation (SHR-Failure and SHR-ISO) and those without LV dilatation (SHR-Failure and SHR-Control) is not likely to be as a consequence of the method of cardiac myocyte isolation. In contrast, the strengths of the present study include the use of two methods of measurement of cardiac myocyte length; the investigation of two models of cardiac dilatation; and the assessment of LV dimensions using load and heart rate independent measures.

From a clinical perspective the present study suggests that in hypertension-induced and beta-adrenergic induced heart failure, models in which the cardiac interstitium plays a major role, alterations in cardiac myocyte dimensions do not contribute to LV dilatation. Hence, in these
models therapy should be aimed at targeting the extracellular matrix rather than growth or hypertrophy of cardiac myocytes.

In conclusion, the present study indicates that although cardiac hypertrophy (in both hypertension-induced and beta-adrenergic-induced models) is associated with increases in cardiac myocyte length, cardiac dilatation in these models is not attributed to alterations in cardiac myocyte dimensions.
CHAPTER 5
5.0 REFERENCES


in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. 


ventricular myocyte apoptosis in adult normotensive rat. *J Mol Cell Cardiol* 34, 1655-1665.


matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. *J Mol Cell Cardiol* **32**, 109-120.


APPENDICES
(Animal Ethics Screening Committee Clearance Certificates)
UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

STRICTLY CONFIDENTIAL

ANIMAL ETHICS SCREENING COMMITTEE (AESC)

CLEARANCE CERTIFICATE NO. 2006/41/05

APPLICANT: Mr RJ Correia

SCHOOL: Physiology

DEPARTMENT: Medical School

LOCATION: 

PROJECT TITLE: Do alterations in cardiac myocyte dimensions contribute to the development of cardiac dilation?

Number and Species

45 SHR and 45 WKY rats (all male)

Approval was given for the use of animals for the project described above at an AESC meeting held on 2005/04/25. This approval remains valid until 2008/02/24.

The use of these animals is subject to AESC guidelines for the use and care of animals, is limited to the procedures described in the application form and to the following additional conditions:

The minimum time between the two procedures must be 7 days.

Signed: __________________________ Date: 06/05/06

Chapperson AESC

I am satisfied that the persons listed in this application are competent to perform the procedures therein, in terms of Section 23 (1) (c) of the Veterinary and Para-Veterinary Professions Act (19 of 1982)

Signed: __________________________ Date: 06/05/06

(Registered Veterinarian)

cc: Supervisor: Professor AJ Woodliff

Director: CAS

Works 2000Main015/AESCCert.wps
AESC 3

STRICTLY CONFIDENTIAL

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

ANIMAL ETHICS SCREENING COMMITTEE

CLEARANCE CERTIFICATE NO. 2002 39 5

APPLICANT: Professor G Norton

DEPARTMENT: School of Physiology

PROJECT TITLE: Effect of Antioxidant and an Aldosterone Receptor Antagonist On Cardiac Remodeling In Adrenergic-Mediated Cardiac Dilatation In Rats

<table>
<thead>
<tr>
<th>Species</th>
<th>Number</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR (rats)</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>WKY (rats)</td>
<td>48</td>
<td>2004</td>
</tr>
</tbody>
</table>

Approval is hereby given for the experiment described in the above application.

The use of these animals is subject to AESC Guidelines for the use and care of animals, is limited to the procedures specified in the application form, and to:

APPROVED

SIGNED

(Chairman: Animal Ethics Screening Committee) DATE: 2 May 2002

ii) I am satisfied that the persons listed in this application are competent to perform the procedures therein, in terms of Section 23(1)(e) of the Veterinary and Para-veterinary Professions Act (19 of 1982)

SIGNED

(Registered Veterinarian) DATE: 2 May 2002

NOTE:

First-time users of the CAS should contact the Director of the CAS in order to familiarise themselves with the facilities available, and the procedures required by the CAS for the carrying out of experiments.
UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

ANIMAL ETHICS SCREENING COMMITTEE

CLEARANCE CERTIFICATE NO. 2002 37 5

APPLICANT: Professor G Norton

DEPARTMENT: School of Physiology

PROJECT TITLE: Effect of Pentoxifylline On Cardiac Remodeling In Adrenergic-Mediated Cardiac Dilatation In Rata

<table>
<thead>
<tr>
<th>Species</th>
<th>Number</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sprague dawley</td>
<td>48</td>
<td>2004</td>
</tr>
<tr>
<td>SHRs (rats)</td>
<td>48</td>
<td>2004</td>
</tr>
<tr>
<td>WKYS (rats)</td>
<td>48</td>
<td>2004</td>
</tr>
</tbody>
</table>

i) Approval is hereby given for the experiment described in the above application.

The use of these animals is subject to AESC Guidelines for the use and care of animals, is limited to the procedures specified in the application form, and to:

APPROVED

SIGNED

(Chairman, Animal Ethics Screening Committee)

DATE: 2 May 2002

ii) I am satisfied that the persons listed in this application are competent to perform the procedures therein, in terms of Section 23(1)(c) of the Veterinary and Para-veterinary Professions Act (19 of 1982)

SIGNED

(Registered Veterinarian)

DATE: 2 May 2002

NOTE:

First-time users of the CAS should contact the Director of the CAS in order to familiarise themselves with the facilities available, and the procedures required by the CAS for the carrying out of experiments.
AESC 3

STRICTLY CONFIDENTIAL

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

ANIMAL ETHICS SCREENING COMMITTEE

CLEARANCE CERTIFICATE NO.: 99 1 2b

APPLICANT: Dr G Norton

DEPARTMENT: Physiology

PROJECT TITLE: Isoprenaline-induced cardiac remodelling: Role of myocardial cross-linked collagen

<table>
<thead>
<tr>
<th>Species</th>
<th>Number</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sprague-Dawley rats</td>
<td>90</td>
<td>27 January 2001</td>
</tr>
<tr>
<td>SHR rats</td>
<td>80</td>
<td>27 January 2001</td>
</tr>
<tr>
<td>WKY rats</td>
<td>80</td>
<td>27 January 2001</td>
</tr>
</tbody>
</table>

i) Approval is hereby given for the experiment described in the above application.

The use of these animals is subject to AESC Guidelines for the use and care of animals, is limited to the procedures specified in the application form, and to:

Nil.

SIGNED G. J. O'Ni Date: 27 January 1999
(Chairman: Animal Ethics Screening Committee)

ii) I am satisfied that the persons listed in this application are competent to perform the procedures therein, in terms of Section 23(1)c of the Veterinary and Para-veterinary Professions Act (19 of 1982)

SIGNED (Registered Veterinarian)

NOTE:
First-time users of the CAS should contact the Director of the CAS in order to familiarise themselves with the facilities available, and the procedures required by the CAS for the carrying out of experiments.
UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

ANIMAL ETHICS SCREENING COMMITTEE

CLEARANCE CERTIFICATE NO: 97 44 5

APPLICANT: Dr G Norton

DEPARTMENT: Physiology

PROJECT TITLE: The influence of an atropeptidase inhibitor on cardiac morphology and performance in hypertensive heart disease

<table>
<thead>
<tr>
<th>Species</th>
<th>Number</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneously hypertensive rats</td>
<td>40</td>
<td>29 May 1999</td>
</tr>
<tr>
<td>Wistar Kyoto rats</td>
<td>20</td>
<td>29 May 1999</td>
</tr>
<tr>
<td>SD rats</td>
<td>90</td>
<td>29 May 1999</td>
</tr>
</tbody>
</table>

First-time users of the CAS should contact the Director of the CAS in order to familiarise themselves with the facilities available.

The use of these animals is subject to AESC Guidelines for the use and care of animals, to the procedures specified in the application form, and to:

a) the animals being monitored daily for the first three weeks of the experimental period, and thereafter once weekly;

b) the end-point regarding weight loss being that should a rat lose more than 15% of its body weight, it will be euthanased.

SIGNED (Chairman: Animal Ethics Screening Committee) DATE: 29 May 1997

Please see attachment: